doxazosin has been researched along with Adenoma, Prostatic in 259 studies
Doxazosin: A prazosin-related compound that is a selective alpha-1-adrenergic blocker.
doxazosin : A member of the class of quinazolines that is quinazoline substituted by an amino group at position 4, methoxy groups at positions 6 and 7 and a piperazin-1-yl group at position 2 which in turn is substituted by a 2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl group at position 4. An antihypertensive agent, it is used in the treatment of high blood pressure.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this randomized controlled trial, 55 sexually active lower urinary tract symptoms/benign prostatic obstruction patients with concomitant erectile dysfunction were randomly allocated in two groups: the first received mirabegron 50 mg plus doxazosin 2 mg once daily (mirabegron group) and the second received tolterodine 4 mg plus doxazosin 2 mg (tolterodine group) for 12 weeks." | 9.51 | Mirabegron for treatment of erectile dysfunction concomitant with lower urinary tract symptoms in patients with benign prostatic obstruction: A randomized controlled trial. ( El-Assmy, A; Elbaz, R; Hashem, A; Shokeir, AA; Zahran, MH, 2022) |
| "Objective To observe the efficacy and safety of Longbishu Capsule (LBS) com- bined Doxazosin Mesylate Tablet (DMT) in treating benign prostatic hyperplasia (BPH)." | 9.22 | [Treatment of Benign Prostatic Hyperplasia by Longbishu Capsule Combined Doxazosin Mesylate Tablet]. ( Chang, DG; Chen, L; Guo, J; Song, CS; Wang, F; Zhang, R; Zhao, JY, 2016) |
| "To compare the efficacy of 4 mg and 8 mg doxazosin XL treatments in patients with benign prostatic hyperplasia-related lower urinary tract symptoms and determine the efficiency of 8 mg in those patients with inadequate response to 4 mg." | 9.20 | Determination of the efficiency of 8 mg doxazosin XL treatment in patients with an inadequate response to 4 mg doxazosin XL treatment for benign prostatic hyperplasia. ( Aslan, Y; Atan, A; Balci, M; Bilgin, O; Dilmen, C; Guzel, O; Keten, T; Ozdemir, U; Tuncel, A; Yahsi, S, 2015) |
| "To assess the clinical effect and safety of the Chinese medicine Longbishu Capsule combined with mesylate doxazosin in the treatment of benign prostatic hyperplasia (BPH) of the kidney deficiency and blood stagnation type." | 9.20 | [Longbishu Capsule combined with mesylate doxazosin: an efficacious therapy for benign prostatic hyperplasia]. ( Bi, MS; Chang, DG; Chen, DA; Li, GS; Peng, CH; Yang, XZ; You, YD; Yu, XJ; Zhang, PH, 2015) |
| "We examined the effects of doxazosin, finasteride and combined therapy in men with lower urinary tract symptoms associated with benign prostatic hyperplasia on sexual function, as assessed by the Brief Male Sexual Function Inventory during 4 years." | 9.19 | Change in sexual function in men with lower urinary tract symptoms/benign prostatic hyperplasia associated with long-term treatment with doxazosin, finasteride and combined therapy. ( Burrows, PK; Eggers, PW; Fwu, CW; Kirkali, Z; Kusek, JW; McVary, KT, 2014) |
| "We aimed to compare the efficacy of isosorbide mononitrate and doxazosin in the treatment of lower urinary tract symptoms (LUTS)." | 9.19 | Comparison of the efficacy of isosorbide mononitrate and doxazosin in the treatment of lower urinary tract symptoms and benign prostatic hyperplasia: a randomized clinical trial. ( Çelik, O; Eryıldırım, B; Faydacı, G; Tarhan, F; Tosun, Ç, 2014) |
| "To investigate the effect of Longbishu Capsule (, LBS), doxazosin, and combination therapy on benign prostatic hyperplasia (BPH)." | 9.19 | Effect of Longbishu capsule () plus doxazosin on benign prostatic hyperplasia: a randomized controlled trial. ( Chang, DG; Chen, L; Guo, J; Song, CS; Wang, F; Zhang, Q; Zhang, R; Zhao, JY, 2014) |
| "We examined the effects of doxazosin, finasteride and combination therapy among men with benign prostatic hyperplasia on quality of life assessed with MOS-SF-36 (Medical Outcomes Study Short-Form 36) and 2 disease specific instruments (BII, benign prostatic hyperplasia Impact Index and I-PSS-QoL, International Prostate Symptom Score-QoL) during 4 years." | 9.17 | Long-term effects of doxazosin, finasteride and combination therapy on quality of life in men with benign prostatic hyperplasia. ( Eggers, PW; Fwu, CW; Kaplan, SA; Kirkali, Z; Kusek, JW; Lee, JY, 2013) |
| "To investigate the safety of daily coadministration of α-blockers with tadalafil 5 mg in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia." | 9.16 | Hemodynamic effects of once-daily tadalafil in men with signs and symptoms of benign prostatic hyperplasia on concomitant α1-adrenergic antagonist therapy: results of a multicenter randomized, double-blind, placebo-controlled trial. ( Brady, E; Clark, WR; Dgetluck, N; Goldfischer, E; Klise, SR; Kowalczyk, JJ; Shane, MA, 2012) |
| "This study sought to investigate the clinical efficacy and safety of combined oral therapy with sildenafil and doxazosin GITS compared to sildenafil monotherapy in treating Chinese patients with erectile dysfunction (ED) and lower urinary tract symptoms secondary to benign prostatic hyperplasia (BPH/LUTS)." | 9.15 | An open, comparative, multicentre clinical study of combined oral therapy with sildenafil and doxazosin GITS for treating Chinese patients with erectile dysfunction and lower urinary tract symptoms secondary to benign prostatic hyperplasia. ( Gao, B; Guo, YL; Jin, Z; Liu, JH; Lu, J; Song, WD; Sun, XZ; Tang, YX; Xin, ZC; Zhang, ZC, 2011) |
| "In Chinese patients with LUTS/BPH, doxazosin-GITS is slightly better than tamsulosin in reducing the frequency of nocturia." | 9.15 | Effect of doxazosin gastrointestinal therapeutic system 4 mg vs tamsulosin 0.2 mg on nocturia in Chinese men with lower urinary tract symptoms: a prospective, multicenter, randomized, open, parallel study. ( Jin, J; Wan, B; Wang, X; Yang, Y; Ye, H; Yu, W; Zhang, K; Zhang, N; Zhong, C, 2011) |
| "To compare the rapidity of improvement in lower urinary tract symptoms (LUTS) for the doxazosin gastrointestinal therapeutic system (GITS) and tamsulosin in benign prostatic hyperplasia (BPH) patients." | 9.15 | Comparative rapid onset of efficacy between doxazosin gastrointestinal therapeutic system and tamsulosin in patients with lower urinary tract symptoms from benign prostatic hyperplasia: a multicentre, prospective, randomised study. ( Chung, BH; Chung, MS; Lee, SH; Park, KK; Yoo, SJ, 2011) |
| "To determine the efficacy and safety of a diuretic agent, frusemide, combined with doxazosin in the treatment of nocturia in patients with benign prostate hyperplasia / lower urinary tract symptoms (BPH/LUTS)." | 9.14 | [Frusemide plus doxazosin therapy for nocturia in patients with BPH/LUTS]. ( Fang, RJ; Huang, SY; Zeng, BW; Zhu, DS; Zhu, SX, 2010) |
| "We investigated the effect of the combination of the doxazosin gastrointestinal therapeutic system and 10 mg vardenafil on the hemodynamic status of patients with benign prostatic hyperplasia and erectile dysfunction." | 9.13 | Effect of vardenafil on blood pressure profile of patients with erectile dysfunction concomitantly treated with doxazosin gastrointestinal therapeutic system for benign prostatic hyperplasia. ( Chan, ES; Cheng, CW; Hou, SM; Ng, CF; Wong, A; Wong, HM, 2008) |
| "To evaluate the efficacy of modified-release doxazosin 4 mg in the treatment of patients with acute urinary retention (AUR) due to benign prostate gland hyperplasia (BPH)." | 9.13 | Efficacy of doxazosin in the treatment of acute urinary retention due to benign prostate hyperplasia. ( López, C; Ortiz, M; Pacheco, JJ; Prieto, L; Romero, J, 2008) |
| "This meta-analysis indicates that doxazosin-GITS has significantly higher efficacy and lower AEs than tamsulosin in patients with lower urinary tract symptoms/benign prostate hyperplasia." | 9.12 | Efficacy and tolerability of doxazosin gastro-intestinal therapeutic system versus tamsulosin in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: A systematic review and meta-analysis. ( Guo, J; Tang, R, 2021) |
| "Brazilian patients with benign prostatic hyperplasia were randomised in a 12-week, double-blind, double-dummy study to receive doxazosin gastrointestinal therapeutic system (GITS) 4 mg q." | 9.12 | A randomised, double-blind study comparing the efficacy and tolerability of controlled-release doxazosin and tamsulosin in the treatment of benign prostatic hyperplasia in Brazil. ( Bertero, E; Cairoli, CE; DA Ros, CT; Damião, R; Koff, WJ; Mesquita, F; Pinheiro, GE; Pompeo, AC; Rosenblatt, C; Wroclawski, ER, 2006) |
| "The objective of the study was to compare the efficacy and safety of tamsulosin hydrochloride and doxazosin in patients with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH)." | 9.12 | Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia. ( Birowo, P; Djati, W; Rahardjo, D; Soebadi, DM; Sugandi, S; Wahyudi, I, 2006) |
| "The efficacy and safety profiles of two alpha1-adrenoceptor antagonists, doxazosin gastrointestinal therapeutic system, a controlled-release formulation of doxazosin, and tamsulosin, were compared in Chinese men with confirmed benign prostatic hyperplasia." | 9.12 | Doxazosin gastrointestinal therapeutic system versus tamsulosin for the treatment of benign prostatic hyperplasia: a study in Chinese patients. ( Ding, Q; He, Z; Wang, J; Xu, K; Xue, Z; Zhang, Y, 2007) |
| "A total of 3,047 men with lower urinary tract symptoms/benign prostatic hyperplasia enrolled in the Medical Therapy of Prostatic Symptoms trial were randomly assigned to receive doxazosin alone, finasteride alone, combination therapy or placebo." | 9.12 | The effect of doxazosin, finasteride and combination therapy on nocturia in men with benign prostatic hyperplasia. ( Burrows, PK; Johnson, TM; Kusek, JW; Lepor, H; Nyberg, LM; Roehrborn, CG; Tenover, JL, 2007) |
| "An analysis is presented to compare the efficacies of the doxazosin gastrointestinal therapeutic system (doxazosin-GITS) and tamsulosin in patients with benign prostatic hyperplasia (BPH), collecting data from a published 20-week, randomized, double-blind, crossover study." | 9.11 | Doxazosin controlled release vs tamsulosin in the management of benign prostatic hyperplasia: an efficacy analysis. ( Jensen, D; Kirby, RS; Mallen, S; Quinn, S, 2004) |
| "Prospective and randomised study to assess the effectiveness of doxazosin in sustained release formulation in Acute Urinary Retention (AUR) treatment due to benign prostatic hyperplasia (BPH)." | 9.11 | [Doxazosin in the gastrointestinal therapeutic system (GITS) formulation and trial without catheter after acute urinary retention due to BPH. Dose increase action on recovery effect]. ( Arango Toro, O; Bielsa Gali, O; Cañis Sánchez, D; Cortadellas Angel, R; Gelabert Mas, A; Lorente Garín, JA, 2004) |
| "Finasteride, which inhibits the enzyme 5 alpha-reductase, reduces prostate size and relieves the symptoms of benign prostatic hyperplasia (BPH) in men with enlarged prostates." | 9.11 | Combination of finasteride and doxazosin for the treatment of benign prostatic hyperplasia. ( Doggrell, SA, 2004) |
| "To report a comprehensive retrospective analysis of the favourable effects of doxazosin extended-release (XL) and doxazosin standard on the sexual health of patients with comorbid benign prostatic hyperplasia (BPH) and erectile dysfunction (ED), augmenting a previous study of 680 patients with symptomatic BPH." | 9.11 | Efficacy of extended-release doxazosin and doxazosin standard in patients with concomitant benign prostatic hyperplasia and sexual dysfunction. ( Carson, C; Kirby, RS; O'Leary, MP, 2005) |
| "To determine the onset of improvement in benign prostatic hyperplasia symptoms in patients after treatment with doxazosin gastrointestinal therapeutic system (DOX GITS) versus placebo." | 9.11 | A double-blind placebo-controlled study evaluating the onset of action of doxazosin gastrointestinal therapeutic system in the treatment of benign prostatic hyperplasia. ( Andersen, M; Kirby, R; Mallen, S; Prajsner, A; Quinn, S; Roehrborn, CG, 2005) |
| "To evaluate the effectiveness and safety of controlled-release doxazosin for benign prostatic hyperplasia (BPH)." | 9.11 | Controlled-release doxazosin in the treatment of benign prostatic hyperplasia. ( Castaño, I; Duran, R; Hernandez, C; Jara, J; Moralejo, M, 2005) |
| "To evaluate the efficacy and tolerability of the selective alpha(1)-adrenergic antagonist doxazosin and the 5-alpha-reductase inhibitor finasteride, alone and in combination, for the symptomatic treatment of benign prostatic hyperplasia." | 9.10 | Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. ( Bartsch, G; Boyle, P; Cary, MM; Grossman, EB; Jardin, A; Kirby, RS; Roehrborn, C; Sweeney, M, 2003) |
| "To compare the effects of the doxazosin gastrointestinal therapeutic system, extended-release (doxazosin-GITS) formulation, and tamsulosin, another alpha1-antagonist, on total International Prostate Symptom Score (IPSS) and maximum urinary flow rate (Qmax) in treating patients with benign prostatic hyperplasia (BPH)." | 9.10 | A randomized, double-blind crossover study of tamsulosin and controlled-release doxazosin in patients with benign prostatic hyperplasia. ( Kirby, RS, 2003) |
| "5 years) involving 3047 men to compare the effects of placebo, doxazosin, finasteride, and combination therapy on measures of the clinical progression of benign prostatic hyperplasia." | 9.10 | The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. ( Andriole, GL; Bautista, OM; Clarke, HS; Crawford, ED; Diokno, A; Dixon, CM; Foley, JP; Foster, HE; Jacobs, SC; Kaplan, SA; Kreder, KJ; Kusek, JW; Lepor, H; Lieber, MM; Lucia, MS; McConnell, JD; McVary, KT; Menon, M; Milam, DF; Miller, GJ; Nyberg, LM; Ramsdell, JW; Roehrborn, CG; Schenkman, NS; Slawin, KM; Smith, JA, 2003) |
| "This randomized, doubleblind, multicenter, parallel-group, placebo-baseline study compared the effects of doxazosin GITS 4 mg or 8 mg once daily with doxazosin standard 1 mg to 8 mg once daily in 678 men with benign prostatic hyperplasia (BPH)." | 9.09 | [Doxazosin in the gastrointestinal therapeutic system (GITS) and doxazosin standard in patients with benign prostatic hyperplasia. Double-blind trial of efficacy and tolerability]. ( Gratzke, P; Kirby, RS, 2000) |
| "To investigate the relationship among doxazosin dose, plasma concentration, and clinical response in 248 hypertensive men with benign prostatic hyperplasia (BPH) in a 16-week, placebo-controlled, double-blind study." | 9.09 | Clinical correlation of maximal urinary flow rate and plasma doxazosin concentrations in the treatment of benign prostatic hyperplasia. Multicenter Study Group. ( Chung, M; Dias, N; Fawzy, A; Gaffney, M; Vashi, V, 1999) |
| "The alpha1-adrenoceptor antagonist doxazosin has proved successful in treating patients with concurrent benign prostatic hyperplasia (BPH) and hypertension in short-term studies." | 9.09 | Long-term (4 year) efficacy and tolerability of doxazosin for the treatment of concurrent benign prostatic hyperplasia and hypertension. ( Cook, E; Fawzy, A; Gonzalez, F; Hendry, A, 1999) |
| " doxazosin for benign prostatic hyperplasia." | 9.09 | A randomized double-blind study assessing 4 versus 8 mg. doxazosin for benign prostatic hyperplasia. ( Emery, RT; Ferguson, SF; Johnson, DE; MacDiarmid, SA; McGuirt-Franklin, R; McIntyre, WJ, 1999) |
| "To evaluate the clinical efficacy of doxazosin for 6 months in the treatment of benign prostatic hyperplasia (BPH)." | 9.09 | [The clinical and flowmetric results of the treatment of benign prostatic hyperplasia with doxazosin]. ( Esteban Fuertes, M; Luengo Alpuente, S; Ramírez Fernández, JC; Resel Estévez, L; Salinas Casado, J; Salomon Moh'd, S; Virseda Chamorro, M, 1999) |
| "In this study, a randomized and placebo controlled trial, we aimed to study the effectiveness and safety of doxazosin based upon urodynamic parameters, especially pressure/flow studies, in men with benign prostatic hyperplasia (BPH)." | 9.09 | Effects of doxazosin in men with benign prostatic hyperplasia: urodynamic assessment. ( Aksoy, Y; Biçgi, O; Demirel, A; Okyar, G; Ozbey, I; Polat, O, 1999) |
| "The alpha(1)-blocker doxazosin mesylate is an established efficacious and welltolerated treatment for benign prostatic hyperplasia (PBH)." | 9.09 | Double-blind trial of the efficacy and tolerability of doxazosin in the gastrointestinal therapeutic system, doxazosin standard, and placebo in patients with benign prostatic hyperplasia. ( Andersen, M; Dahlstrand, C; Høye, K, 2000) |
| "To report an integrated analysis of two previous studies fully characterizing the clinical utility of the controlled-release gastrointestinal therapeutic system (GITS) formulation of doxazosin in the treatment of benign prostatic hyperplasia (BPH)." | 9.09 | A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia. ( Andersen, M; Dahlstrand, C; Gratzke, P; Høye, K; Kirby, RS, 2001) |
| "A 16-week, double-blind, placebo controlled, dose titration study was done on 100 normotensive patients age 45 years or older to determine the efficacy and safety of doxazosin, a selective alpha 1-adrenoceptor antagonist, in the treatment of benign prostatic hyperplasia (BPH)." | 9.08 | Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. ( Braun, K; Dias, N; Fawzy, A; Gaffney, M; Ice, K; Lewis, GP, 1995) |
| "To assess the effects of doxazosin, a selective alpha 1 adrenoceptor inhibitor, on blood pressure and urinary flow in normotensive and hypertensive (sitting diastolic blood pressure more than 90 mm Hg) men with prostatic hyperplasia (BPH)." | 9.08 | Doxazosin in benign prostatic hyperplasia: effects on blood pressure and urinary flow in normotensive and hypertensive men. ( Kirby, RS, 1995) |
| "To compare the effects of doxazosin on blood pressure when used for the treatment of benign prostatic hyperplasia (BPH) in men who are either physiologically or pharmacologically normotensive." | 9.08 | Doxazosin in physiologically and pharmacologically normotensive men with benign prostatic hyperplasia. ( Kaplan, SA; Meade-D'Alisera, P; Quiñones, S; Soldo, KA, 1995) |
| "This is a controlled efficacy study with doxazosin (4 mg/day) in the long-term management of 64 ambulatory patients with benign prostatic hyperplasia (BPH)." | 9.08 | Doxazosin--an alpha-1 receptor blocking agent in the long-term management of benign prostatic hyperplasia (Part One). ( Dutkiewicz, S; Witeska, A, 1995) |
| "To present the results of a pooled analysis of three double-blind, placebo-controlled studies of doxazosin in benign prostatic hyperplasia (BPH)." | 9.08 | Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. ( Roehrborn, CG; Siegel, RL, 1996) |
| "We evaluated the sustained efficacy and safety of doxazosin for long-term treatment (up to 48 months) of normotensive and hypertensive patients with benign prostatic hyperplasia (BPH)." | 9.08 | Doxazosin for benign prostatic hyperplasia: long-term efficacy and safety in hypertensive and normotensive patients. The Multicenter Study Group. ( Dias, N; Fawzy, A; Gaffney, M; Ice, K; Kaplan, SA; Klimberg, I; Lepor, H; Mobley, DF, 1997) |
| "In a placebo-controlled study, the safety and efficacy of the selective alpha 1-adrenoceptor-blocking agent doxazosin 4 mg once daily in the symptomatic treatment of benign prostatic hyperplasia (BPH) were evaluated." | 9.07 | 29-week doxazosin treatment in patients with symptomatic benign prostatic hyperplasia. A double-blind placebo-controlled study. ( Bendix Holme, J; Christensen, MM; Elkjaer Husted, S; Jacobsen, F; Nielsen, J; Noer, I; Nørgaard, JP; Olesen, S; Rasmussen, PC; Wolf, H, 1994) |
| "Doxazosin is an effective treatment for patients with hypertension, benign prostatic hyperplasia (BPH) and the two comorbidly." | 8.82 | Effect of doxazosin GITS on blood pressure in hypertensive and normotensive patients: a review of hypertension and BPH studies. ( Kirby, RS; Lund-Johansen, P, 2003) |
| "Clinical studies have demonstrated that doxazosin therapy reduced blood pressure (BP) in patients with benign prostatic hyperplasia (BPH) who were hypertensive at baseline but not in patients who were physiologically or pharmacologically normotensive at baseline." | 8.82 | Clinical ease of using doxazosin in BPH patients with and without hypertension. ( Kirby, RS; Steers, WD, 2005) |
| "Doxazosin, a well established treatment in patients with bothersome lower urinary tract symptoms from benign prostatic hyperplasia (BPH), is available in a new controlled-release formulation, doxazosin gastrointestinal therapeutic system (GITS)." | 8.82 | Doxazosin gastrointestinal therapeutic system: a review of its use in benign prostatic hyperplasia. ( Goldsmith, DR; Plosker, GL, 2005) |
| "The association between intraoperative floppy iris syndrome (IFIS) and tamsulosin has been well-described." | 7.79 | Intraoperative floppy iris syndrome (IFIS) in patients receiving tamsulosin or doxazosin-a UK-based comparison of incidence and complication rates. ( Al-Ahmar, B; Haridas, A; Hingorani, M; Syrimi, M, 2013) |
| "The treatment of benign prostatic hyperplasia can be accomplished by the use of different drugs including, doxazosin, an α-1 adrenergic antagonist, and finasteride (FIN), a 5-α reductase inhibitor." | 7.79 | Development of a doxazosin and finasteride transdermal system for combination therapy of benign prostatic hyperplasia. ( Abrahim-Vieira, B; Cabral, LM; De Sousa, VP; Do Carmo, FA; Lopes, M; Padula, C; Pupe, CG; Ribeiro, AJ; Rodrigues, CR; Santi, P; Veiga, F, 2013) |
| "To evaluate the influence of doxazosin and finasteride on histologic findings in benign prostatic hyperplasia accompanied by prostatitis, and to examine the factors related with prostate carcinogenesis." | 7.74 | Histologic influence of doxazosin and finasteride in benign prostatic hyperplasia accompanying chronic inflammation. ( Park, DS; Shim, JY, 2008) |
| "To assess the long-term efficacy and safety of extended-release doxazosin gastrointestinal therapeutic system (GITS) under routine clinical care conditions over 12 months in Korean men with benign prostatic hyperplasia (BPH) with and without coexisting hypertension." | 7.73 | Long-term follow-up study to evaluate the efficacy and safety of the doxazosin gastrointestinal therapeutic system in patients with benign prostatic hyperplasia with or without concomitant hypertension. ( Chung, BH; Hong, SJ, 2006) |
| "The Proscar Long-Term Efficacy and Safety Study (PLESS) and the Medical Therapy of Prostatic Symptoms (MTOPS) study provide new evidence regarding the benefits of finasteride in the treatment of benign prostatic hyperplasia (BPH)." | 7.72 | An economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia. ( Bernard, L; Brisson, M; Hux, M; McDonald, H; Nickel, JC, 2004) |
| " Because benign prostatic hyperplasia (BPH) can give rise to irritative (hypersensory) voiding patterns, we questioned whether the bladder urothelium from patients with BPH released more ATP during in vitro stretch and whether doxazosin, an alpha(1)-adrenoceptor blocker, affects this purinergic mechanism." | 7.71 | Effect of doxazosin on stretch-activated adenosine triphosphate release in bladder urothelial cells from patients with benign prostatic hyperplasia. ( Chai, TC; Jacobs, SC; MaLossi, J; Sun, Y, 2002) |
| "The aim of our study is to verify the effects of doxazosin on sexual function in patients with benign prostatic hyperplasia (BPH)." | 7.71 | Observational multicentric trial performed with doxazosin: evaluation of sexual effects on patients with diagnosed benign prostatic hyperplasia. ( Belgrano, E; Bonini, F; Carmignani, G; Catuogno, C; Corbu, C; De Rose, AF; Di Trapani, D; Fontana, D; Giglio, M; Maver, A; Mirone, V; Muzzonigro, G; Naselli, A; Traverso, P, 2002) |
| "The molecular mechanisms underlying the therapeutic effect of the alpha1 blocker, doxazosin, on benign prostatic hyperplasia (BPH) are poorly understood." | 7.70 | Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia. ( Alexander, R; Borkowski, A; Jacobs, SC; Kyprianou, N; Litvak, JP, 1998) |
| "Recent evidence indicated that an alpha 1 blocker, doxazosin, induces prostate apoptosis in patients with benign prostatic hyperplasia (BPH)." | 7.70 | Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia. ( Borkowski, A; Chon, JK; Isaacs, JT; Jacobs, SC; Kyprianou, N; Partin, AW, 1999) |
| " Alpha blockers in combination with muscarinic receptor antagonists may have the potential to improve symptoms." | 6.82 | A Randomized, Open-Label, Comparative Study of Efficacy and Safety of Tolterodine Combined with Tamsulosin or Doxazosin in Patients with Benign Prostatic Hyperplasia. ( Cao, Y; Chen, T; Guo, L; Niu, H; Wang, Y; Yang, X, 2016) |
| "Few studies have reported the treatment of benign prostatic hyperplasia (BPH) in Asian patients." | 6.71 | Doxazosin for benign prostatic hyperplasia: an open-label, baseline-controlled study in Korean general practice. ( Chung, BH; Hong, SJ; Lee, MS, 2005) |
| "A total of 248 hypertensive patients 45 years old or older with benign prostatic hyperplasia (BPH) was included in this 16-week, multicenter, double-blind, placebo-controlled, parallel-group dose-response study." | 6.68 | Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose-response multicenter study. ( Chrysant, SG; Conn, RL; Dias, N; Gaffney, M; Gillenwater, JY; Ice, K; Roy, J, 1995) |
| "Both doxazosin and terazosin were significantly more likely than finasteride to improve peak urine flow and nocturia, versus finasteride." | 6.46 | Finasteride for benign prostatic hyperplasia. ( Fink, HA; Macdonald, R; Rutks, I; Tacklind, J; Wilt, TJ, 2010) |
| "Benign prostatic hyperplasia is an increasingly prevalent condition affecting > 50% of men > 65 years of age." | 6.44 | Finasteride and doxazosin alone or in combination for the treatment of benign prostatic hyperplasia. ( Bhardwa, J; Goldstraw, M; Kirby, R; Tzortzis, S, 2007) |
| "The therapeutic goal of treating benign prostatic hyperplasia (BPH) through early detection and effective therapy is to relieve the symptoms, improve patients' quality of life, decrease postvoid residual urine volume, and prevent the associated morbidity when the condition remains untreated." | 6.43 | The clinical efficacy and tolerability of doxazosin standard and gastrointestinal therapeutic system for benign prostatic hyperplasia. ( Desgrandchamps, F; Fitzpatrick, JM, 2005) |
| "Doxazosin mesylate is an alpha1-adrenoceptor antagonist that was used to treat hypertension until a major study (ALLHAT; Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial) showed that it increased the risk of progressing to heart failure." | 6.42 | After ALLHAT: doxazosin for the treatment of benign prostatic hyperplasia. ( Doggrell, SA, 2004) |
| "The prevalence of both benign prostatic hyperplasia (BPH) and hypertension increases with advancing age." | 6.41 | The effect of doxazosin on sexual function in patients with benign prostatic hyperplasia, hypertension, or both. ( Flack, JM, 2002) |
| "Doxazosin is a long-acting alpha 1-adrenoceptor antagonist structurally related to prazosin and terazosin." | 6.39 | Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia. ( Fulton, B; Sorkin, EM; Wagstaff, AJ, 1995) |
| "Doxazosin is a selective alpha 1 antagonist with a long half-life and gradual onset of action, which make it suitable for once-daily treatment." | 6.39 | Profile of doxazosin in patients with benign prostatic hyperplasia. ( Janknegt, RA, 1995) |
| "In this randomized controlled trial, 55 sexually active lower urinary tract symptoms/benign prostatic obstruction patients with concomitant erectile dysfunction were randomly allocated in two groups: the first received mirabegron 50 mg plus doxazosin 2 mg once daily (mirabegron group) and the second received tolterodine 4 mg plus doxazosin 2 mg (tolterodine group) for 12 weeks." | 5.51 | Mirabegron for treatment of erectile dysfunction concomitant with lower urinary tract symptoms in patients with benign prostatic obstruction: A randomized controlled trial. ( El-Assmy, A; Elbaz, R; Hashem, A; Shokeir, AA; Zahran, MH, 2022) |
| "Medications targeting androgen receptor activity (eg finasteride) or smooth muscle contractility (eg doxazosin) do not resolve lower urinary tract symptoms indicative of lower urinary tract dysfunction in an important subgroup of men." | 5.30 | Prostate Transition Zone Fibrosis is Associated with Clinical Progression in the MTOPS Study. ( Leverson, GE; Macoska, JA; McVary, KT; Ricke, WA; Uchtmann, KS, 2019) |
| "Doxazosin treatment resulted in improvements in both urodynamic and symptomatic parameters associated with BPH." | 5.29 | Efficacy and safety of the alpha-1 blocker doxazosin in the treatment of benign prostatic hyperplasia. Analysis of 5 studies. Doxazosin Study Groups. ( Chapple, CR; Janknegt, RA, 1993) |
| "Doxazosin has a slower onset of action and longer plasma half-life than any other available selective alpha 1-adrenoceptor inhibitor, which may confer advantages in terms of tolerability over the more rapidly absorbed and eliminated selective alpha 1-adrenoceptor inhibitors." | 5.29 | Profile of doxazosin in the hypertensive man with benign prostatic hyperplasia. ( Kirby, RS, 1994) |
| " Doxazosin in the management of arterial hypertension was associated with a higher risk of cardiovascular disease, particularly heart failure, than chlorthalidone." | 5.22 | Efficacy and safety of adrenergic alpha-1 receptor antagonists in older adults: a systematic review and meta-analysis supporting the development of recommendations to reduce potentially inappropriate prescribing. ( Kienberger, G; Mann, E; Mansbart, F; Sönnichsen, A, 2022) |
| "Objective To observe the efficacy and safety of Longbishu Capsule (LBS) com- bined Doxazosin Mesylate Tablet (DMT) in treating benign prostatic hyperplasia (BPH)." | 5.22 | [Treatment of Benign Prostatic Hyperplasia by Longbishu Capsule Combined Doxazosin Mesylate Tablet]. ( Chang, DG; Chen, L; Guo, J; Song, CS; Wang, F; Zhang, R; Zhao, JY, 2016) |
| "To compare the efficacy of 4 mg and 8 mg doxazosin XL treatments in patients with benign prostatic hyperplasia-related lower urinary tract symptoms and determine the efficiency of 8 mg in those patients with inadequate response to 4 mg." | 5.20 | Determination of the efficiency of 8 mg doxazosin XL treatment in patients with an inadequate response to 4 mg doxazosin XL treatment for benign prostatic hyperplasia. ( Aslan, Y; Atan, A; Balci, M; Bilgin, O; Dilmen, C; Guzel, O; Keten, T; Ozdemir, U; Tuncel, A; Yahsi, S, 2015) |
| "To assess the clinical effect and safety of the Chinese medicine Longbishu Capsule combined with mesylate doxazosin in the treatment of benign prostatic hyperplasia (BPH) of the kidney deficiency and blood stagnation type." | 5.20 | [Longbishu Capsule combined with mesylate doxazosin: an efficacious therapy for benign prostatic hyperplasia]. ( Bi, MS; Chang, DG; Chen, DA; Li, GS; Peng, CH; Yang, XZ; You, YD; Yu, XJ; Zhang, PH, 2015) |
| "We examined the effects of doxazosin, finasteride and combined therapy in men with lower urinary tract symptoms associated with benign prostatic hyperplasia on sexual function, as assessed by the Brief Male Sexual Function Inventory during 4 years." | 5.19 | Change in sexual function in men with lower urinary tract symptoms/benign prostatic hyperplasia associated with long-term treatment with doxazosin, finasteride and combined therapy. ( Burrows, PK; Eggers, PW; Fwu, CW; Kirkali, Z; Kusek, JW; McVary, KT, 2014) |
| "We aimed to compare the efficacy of isosorbide mononitrate and doxazosin in the treatment of lower urinary tract symptoms (LUTS)." | 5.19 | Comparison of the efficacy of isosorbide mononitrate and doxazosin in the treatment of lower urinary tract symptoms and benign prostatic hyperplasia: a randomized clinical trial. ( Çelik, O; Eryıldırım, B; Faydacı, G; Tarhan, F; Tosun, Ç, 2014) |
| "To investigate the effect of Longbishu Capsule (, LBS), doxazosin, and combination therapy on benign prostatic hyperplasia (BPH)." | 5.19 | Effect of Longbishu capsule () plus doxazosin on benign prostatic hyperplasia: a randomized controlled trial. ( Chang, DG; Chen, L; Guo, J; Song, CS; Wang, F; Zhang, Q; Zhang, R; Zhao, JY, 2014) |
| "We examined the effects of doxazosin, finasteride and combination therapy among men with benign prostatic hyperplasia on quality of life assessed with MOS-SF-36 (Medical Outcomes Study Short-Form 36) and 2 disease specific instruments (BII, benign prostatic hyperplasia Impact Index and I-PSS-QoL, International Prostate Symptom Score-QoL) during 4 years." | 5.17 | Long-term effects of doxazosin, finasteride and combination therapy on quality of life in men with benign prostatic hyperplasia. ( Eggers, PW; Fwu, CW; Kaplan, SA; Kirkali, Z; Kusek, JW; Lee, JY, 2013) |
| "To investigate the safety of daily coadministration of α-blockers with tadalafil 5 mg in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia." | 5.16 | Hemodynamic effects of once-daily tadalafil in men with signs and symptoms of benign prostatic hyperplasia on concomitant α1-adrenergic antagonist therapy: results of a multicenter randomized, double-blind, placebo-controlled trial. ( Brady, E; Clark, WR; Dgetluck, N; Goldfischer, E; Klise, SR; Kowalczyk, JJ; Shane, MA, 2012) |
| "This study sought to investigate the clinical efficacy and safety of combined oral therapy with sildenafil and doxazosin GITS compared to sildenafil monotherapy in treating Chinese patients with erectile dysfunction (ED) and lower urinary tract symptoms secondary to benign prostatic hyperplasia (BPH/LUTS)." | 5.15 | An open, comparative, multicentre clinical study of combined oral therapy with sildenafil and doxazosin GITS for treating Chinese patients with erectile dysfunction and lower urinary tract symptoms secondary to benign prostatic hyperplasia. ( Gao, B; Guo, YL; Jin, Z; Liu, JH; Lu, J; Song, WD; Sun, XZ; Tang, YX; Xin, ZC; Zhang, ZC, 2011) |
| "In Chinese patients with LUTS/BPH, doxazosin-GITS is slightly better than tamsulosin in reducing the frequency of nocturia." | 5.15 | Effect of doxazosin gastrointestinal therapeutic system 4 mg vs tamsulosin 0.2 mg on nocturia in Chinese men with lower urinary tract symptoms: a prospective, multicenter, randomized, open, parallel study. ( Jin, J; Wan, B; Wang, X; Yang, Y; Ye, H; Yu, W; Zhang, K; Zhang, N; Zhong, C, 2011) |
| "To compare the rapidity of improvement in lower urinary tract symptoms (LUTS) for the doxazosin gastrointestinal therapeutic system (GITS) and tamsulosin in benign prostatic hyperplasia (BPH) patients." | 5.15 | Comparative rapid onset of efficacy between doxazosin gastrointestinal therapeutic system and tamsulosin in patients with lower urinary tract symptoms from benign prostatic hyperplasia: a multicentre, prospective, randomised study. ( Chung, BH; Chung, MS; Lee, SH; Park, KK; Yoo, SJ, 2011) |
| "To compare the efficacy and safety of a combination therapy, doxazosin plus tenoxicam, and doxazosin alone for lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH), as various combination therapies increase the efficacy of medical therapy." | 5.14 | Combination therapy with doxazosin and tenoxicam for the management of lower urinary tract symptoms. ( Aslan, G; Bozkurt, O; Demir, O; Esen, AA; Ozdemir, I, 2009) |
| "In this study we aimed to evaluate the impact of doxazosin treatment on erectile functions in patients with lower urinary tract symptoms (LUTS) and having erectile dysfunction (ED) at baseline." | 5.14 | The effect of alpha-blocker therapy on erectile functions in patients with lower urinary tract symptoms due to benign prostate hyperplasia. ( Aslan, G; Bozkurt, O; Demir, O; Esen, AA; Ozdemir, I, 2009) |
| "This study was carried out to obtain information on the efficacy and safety of the controlled release formulation of the doxazosin Gastrointestinal Therapeutic System (GITS) in Taiwanese subjects with benign prostatic hyperplasia (BPH)." | 5.14 | Efficacy and safety of the doxazosin gastrointestinal therapeutic system for the treatment of benign prostate hyperplasia. ( Chang, CH; Cheng, CL; Schou, M; Sun, GH; Tsui, KH; Wu, TT, 2010) |
| "To evaluate the clinical efficacy of Cardura XL (doxazosin mesylate controlled release tablets) on lower urinary tract symptoms, IPSS (international prognostic scoring system) and short-term QOL (quality of life) (3 months) in the treatment of benign prostatic hyperplasia (BPH)." | 5.14 | [Clinical efficacy of a short-term regimen of Cardura XL on lower urinary tract symptoms and international prognostic scoring system in the treatment of benign prostatic hyperplasia]. ( Wu, ZJ; Yang, Y; Zhang, P; Zhang, XD, 2010) |
| "To determine the efficacy and safety of a diuretic agent, frusemide, combined with doxazosin in the treatment of nocturia in patients with benign prostate hyperplasia / lower urinary tract symptoms (BPH/LUTS)." | 5.14 | [Frusemide plus doxazosin therapy for nocturia in patients with BPH/LUTS]. ( Fang, RJ; Huang, SY; Zeng, BW; Zhu, DS; Zhu, SX, 2010) |
| "We investigated the effect of the combination of the doxazosin gastrointestinal therapeutic system and 10 mg vardenafil on the hemodynamic status of patients with benign prostatic hyperplasia and erectile dysfunction." | 5.13 | Effect of vardenafil on blood pressure profile of patients with erectile dysfunction concomitantly treated with doxazosin gastrointestinal therapeutic system for benign prostatic hyperplasia. ( Chan, ES; Cheng, CW; Hou, SM; Ng, CF; Wong, A; Wong, HM, 2008) |
| "In this MTOPS data analysis long-term (more than 4 years) treatment with finasteride, either alone or in combination with doxazosin, led to a consistent, clinically significant reduction in total prostate volume compared to placebo in patients with lower urinary tract symptoms and benign prostatic hyperplasia whose baseline prostate size ranged from relatively small (less than 25 to 30 ml) to enlarged (40 ml or greater)." | 5.13 | Long-term treatment with finasteride results in a clinically significant reduction in total prostate volume compared to placebo over the full range of baseline prostate sizes in men enrolled in the MTOPS trial. ( Kaplan, SA; Kusek, JW; Lee, JY; McConnell, JD; Meehan, AG; Nyberg, LM; Roehrborn, CG; Rotonda, J; Surynawanshi, S, 2008) |
| "To evaluate the efficacy of modified-release doxazosin 4 mg in the treatment of patients with acute urinary retention (AUR) due to benign prostate gland hyperplasia (BPH)." | 5.13 | Efficacy of doxazosin in the treatment of acute urinary retention due to benign prostate hyperplasia. ( López, C; Ortiz, M; Pacheco, JJ; Prieto, L; Romero, J, 2008) |
| "This meta-analysis indicates that doxazosin-GITS has significantly higher efficacy and lower AEs than tamsulosin in patients with lower urinary tract symptoms/benign prostate hyperplasia." | 5.12 | Efficacy and tolerability of doxazosin gastro-intestinal therapeutic system versus tamsulosin in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: A systematic review and meta-analysis. ( Guo, J; Tang, R, 2021) |
| "Brazilian patients with benign prostatic hyperplasia were randomised in a 12-week, double-blind, double-dummy study to receive doxazosin gastrointestinal therapeutic system (GITS) 4 mg q." | 5.12 | A randomised, double-blind study comparing the efficacy and tolerability of controlled-release doxazosin and tamsulosin in the treatment of benign prostatic hyperplasia in Brazil. ( Bertero, E; Cairoli, CE; DA Ros, CT; Damião, R; Koff, WJ; Mesquita, F; Pinheiro, GE; Pompeo, AC; Rosenblatt, C; Wroclawski, ER, 2006) |
| "The objective of the study was to compare the efficacy and safety of tamsulosin hydrochloride and doxazosin in patients with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH)." | 5.12 | Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia. ( Birowo, P; Djati, W; Rahardjo, D; Soebadi, DM; Sugandi, S; Wahyudi, I, 2006) |
| "The efficacy and safety profiles of two alpha1-adrenoceptor antagonists, doxazosin gastrointestinal therapeutic system, a controlled-release formulation of doxazosin, and tamsulosin, were compared in Chinese men with confirmed benign prostatic hyperplasia." | 5.12 | Doxazosin gastrointestinal therapeutic system versus tamsulosin for the treatment of benign prostatic hyperplasia: a study in Chinese patients. ( Ding, Q; He, Z; Wang, J; Xu, K; Xue, Z; Zhang, Y, 2007) |
| "A total of 3,047 men with lower urinary tract symptoms/benign prostatic hyperplasia enrolled in the Medical Therapy of Prostatic Symptoms trial were randomly assigned to receive doxazosin alone, finasteride alone, combination therapy or placebo." | 5.12 | The effect of doxazosin, finasteride and combination therapy on nocturia in men with benign prostatic hyperplasia. ( Burrows, PK; Johnson, TM; Kusek, JW; Lepor, H; Nyberg, LM; Roehrborn, CG; Tenover, JL, 2007) |
| "An analysis is presented to compare the efficacies of the doxazosin gastrointestinal therapeutic system (doxazosin-GITS) and tamsulosin in patients with benign prostatic hyperplasia (BPH), collecting data from a published 20-week, randomized, double-blind, crossover study." | 5.11 | Doxazosin controlled release vs tamsulosin in the management of benign prostatic hyperplasia: an efficacy analysis. ( Jensen, D; Kirby, RS; Mallen, S; Quinn, S, 2004) |
| "Prospective and randomised study to assess the effectiveness of doxazosin in sustained release formulation in Acute Urinary Retention (AUR) treatment due to benign prostatic hyperplasia (BPH)." | 5.11 | [Doxazosin in the gastrointestinal therapeutic system (GITS) formulation and trial without catheter after acute urinary retention due to BPH. Dose increase action on recovery effect]. ( Arango Toro, O; Bielsa Gali, O; Cañis Sánchez, D; Cortadellas Angel, R; Gelabert Mas, A; Lorente Garín, JA, 2004) |
| "Finasteride, which inhibits the enzyme 5 alpha-reductase, reduces prostate size and relieves the symptoms of benign prostatic hyperplasia (BPH) in men with enlarged prostates." | 5.11 | Combination of finasteride and doxazosin for the treatment of benign prostatic hyperplasia. ( Doggrell, SA, 2004) |
| "To report a comprehensive retrospective analysis of the favourable effects of doxazosin extended-release (XL) and doxazosin standard on the sexual health of patients with comorbid benign prostatic hyperplasia (BPH) and erectile dysfunction (ED), augmenting a previous study of 680 patients with symptomatic BPH." | 5.11 | Efficacy of extended-release doxazosin and doxazosin standard in patients with concomitant benign prostatic hyperplasia and sexual dysfunction. ( Carson, C; Kirby, RS; O'Leary, MP, 2005) |
| "To determine the onset of improvement in benign prostatic hyperplasia symptoms in patients after treatment with doxazosin gastrointestinal therapeutic system (DOX GITS) versus placebo." | 5.11 | A double-blind placebo-controlled study evaluating the onset of action of doxazosin gastrointestinal therapeutic system in the treatment of benign prostatic hyperplasia. ( Andersen, M; Kirby, R; Mallen, S; Prajsner, A; Quinn, S; Roehrborn, CG, 2005) |
| "To evaluate the effectiveness and safety of controlled-release doxazosin for benign prostatic hyperplasia (BPH)." | 5.11 | Controlled-release doxazosin in the treatment of benign prostatic hyperplasia. ( Castaño, I; Duran, R; Hernandez, C; Jara, J; Moralejo, M, 2005) |
| "To evaluate the efficacy and tolerability of the selective alpha(1)-adrenergic antagonist doxazosin and the 5-alpha-reductase inhibitor finasteride, alone and in combination, for the symptomatic treatment of benign prostatic hyperplasia." | 5.10 | Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. ( Bartsch, G; Boyle, P; Cary, MM; Grossman, EB; Jardin, A; Kirby, RS; Roehrborn, C; Sweeney, M, 2003) |
| "To compare the effects of the doxazosin gastrointestinal therapeutic system, extended-release (doxazosin-GITS) formulation, and tamsulosin, another alpha1-antagonist, on total International Prostate Symptom Score (IPSS) and maximum urinary flow rate (Qmax) in treating patients with benign prostatic hyperplasia (BPH)." | 5.10 | A randomized, double-blind crossover study of tamsulosin and controlled-release doxazosin in patients with benign prostatic hyperplasia. ( Kirby, RS, 2003) |
| "5 years) involving 3047 men to compare the effects of placebo, doxazosin, finasteride, and combination therapy on measures of the clinical progression of benign prostatic hyperplasia." | 5.10 | The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. ( Andriole, GL; Bautista, OM; Clarke, HS; Crawford, ED; Diokno, A; Dixon, CM; Foley, JP; Foster, HE; Jacobs, SC; Kaplan, SA; Kreder, KJ; Kusek, JW; Lepor, H; Lieber, MM; Lucia, MS; McConnell, JD; McVary, KT; Menon, M; Milam, DF; Miller, GJ; Nyberg, LM; Ramsdell, JW; Roehrborn, CG; Schenkman, NS; Slawin, KM; Smith, JA, 2003) |
| "This randomized, doubleblind, multicenter, parallel-group, placebo-baseline study compared the effects of doxazosin GITS 4 mg or 8 mg once daily with doxazosin standard 1 mg to 8 mg once daily in 678 men with benign prostatic hyperplasia (BPH)." | 5.09 | [Doxazosin in the gastrointestinal therapeutic system (GITS) and doxazosin standard in patients with benign prostatic hyperplasia. Double-blind trial of efficacy and tolerability]. ( Gratzke, P; Kirby, RS, 2000) |
| "To investigate the relationship among doxazosin dose, plasma concentration, and clinical response in 248 hypertensive men with benign prostatic hyperplasia (BPH) in a 16-week, placebo-controlled, double-blind study." | 5.09 | Clinical correlation of maximal urinary flow rate and plasma doxazosin concentrations in the treatment of benign prostatic hyperplasia. Multicenter Study Group. ( Chung, M; Dias, N; Fawzy, A; Gaffney, M; Vashi, V, 1999) |
| "The alpha1-adrenoceptor antagonist doxazosin has proved successful in treating patients with concurrent benign prostatic hyperplasia (BPH) and hypertension in short-term studies." | 5.09 | Long-term (4 year) efficacy and tolerability of doxazosin for the treatment of concurrent benign prostatic hyperplasia and hypertension. ( Cook, E; Fawzy, A; Gonzalez, F; Hendry, A, 1999) |
| " doxazosin for benign prostatic hyperplasia." | 5.09 | A randomized double-blind study assessing 4 versus 8 mg. doxazosin for benign prostatic hyperplasia. ( Emery, RT; Ferguson, SF; Johnson, DE; MacDiarmid, SA; McGuirt-Franklin, R; McIntyre, WJ, 1999) |
| "To evaluate the clinical efficacy of doxazosin for 6 months in the treatment of benign prostatic hyperplasia (BPH)." | 5.09 | [The clinical and flowmetric results of the treatment of benign prostatic hyperplasia with doxazosin]. ( Esteban Fuertes, M; Luengo Alpuente, S; Ramírez Fernández, JC; Resel Estévez, L; Salinas Casado, J; Salomon Moh'd, S; Virseda Chamorro, M, 1999) |
| "In this study, a randomized and placebo controlled trial, we aimed to study the effectiveness and safety of doxazosin based upon urodynamic parameters, especially pressure/flow studies, in men with benign prostatic hyperplasia (BPH)." | 5.09 | Effects of doxazosin in men with benign prostatic hyperplasia: urodynamic assessment. ( Aksoy, Y; Biçgi, O; Demirel, A; Okyar, G; Ozbey, I; Polat, O, 1999) |
| "The alpha(1)-blocker doxazosin mesylate is an established efficacious and welltolerated treatment for benign prostatic hyperplasia (PBH)." | 5.09 | Double-blind trial of the efficacy and tolerability of doxazosin in the gastrointestinal therapeutic system, doxazosin standard, and placebo in patients with benign prostatic hyperplasia. ( Andersen, M; Dahlstrand, C; Høye, K, 2000) |
| "To report an integrated analysis of two previous studies fully characterizing the clinical utility of the controlled-release gastrointestinal therapeutic system (GITS) formulation of doxazosin in the treatment of benign prostatic hyperplasia (BPH)." | 5.09 | A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia. ( Andersen, M; Dahlstrand, C; Gratzke, P; Høye, K; Kirby, RS, 2001) |
| "A 16-week, double-blind, placebo controlled, dose titration study was done on 100 normotensive patients age 45 years or older to determine the efficacy and safety of doxazosin, a selective alpha 1-adrenoceptor antagonist, in the treatment of benign prostatic hyperplasia (BPH)." | 5.08 | Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. ( Braun, K; Dias, N; Fawzy, A; Gaffney, M; Ice, K; Lewis, GP, 1995) |
| "To assess the effects of doxazosin, a selective alpha 1 adrenoceptor inhibitor, on blood pressure and urinary flow in normotensive and hypertensive (sitting diastolic blood pressure more than 90 mm Hg) men with prostatic hyperplasia (BPH)." | 5.08 | Doxazosin in benign prostatic hyperplasia: effects on blood pressure and urinary flow in normotensive and hypertensive men. ( Kirby, RS, 1995) |
| "To compare the effects of doxazosin on blood pressure when used for the treatment of benign prostatic hyperplasia (BPH) in men who are either physiologically or pharmacologically normotensive." | 5.08 | Doxazosin in physiologically and pharmacologically normotensive men with benign prostatic hyperplasia. ( Kaplan, SA; Meade-D'Alisera, P; Quiñones, S; Soldo, KA, 1995) |
| "This is a controlled efficacy study with doxazosin (4 mg/day) in the long-term management of 64 ambulatory patients with benign prostatic hyperplasia (BPH)." | 5.08 | Doxazosin--an alpha-1 receptor blocking agent in the long-term management of benign prostatic hyperplasia (Part One). ( Dutkiewicz, S; Witeska, A, 1995) |
| "To present the results of a pooled analysis of three double-blind, placebo-controlled studies of doxazosin in benign prostatic hyperplasia (BPH)." | 5.08 | Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. ( Roehrborn, CG; Siegel, RL, 1996) |
| "We evaluated the sustained efficacy and safety of doxazosin for long-term treatment (up to 48 months) of normotensive and hypertensive patients with benign prostatic hyperplasia (BPH)." | 5.08 | Doxazosin for benign prostatic hyperplasia: long-term efficacy and safety in hypertensive and normotensive patients. The Multicenter Study Group. ( Dias, N; Fawzy, A; Gaffney, M; Ice, K; Kaplan, SA; Klimberg, I; Lepor, H; Mobley, DF, 1997) |
| "In a placebo-controlled study, the safety and efficacy of the selective alpha 1-adrenoceptor-blocking agent doxazosin 4 mg once daily in the symptomatic treatment of benign prostatic hyperplasia (BPH) were evaluated." | 5.07 | 29-week doxazosin treatment in patients with symptomatic benign prostatic hyperplasia. A double-blind placebo-controlled study. ( Bendix Holme, J; Christensen, MM; Elkjaer Husted, S; Jacobsen, F; Nielsen, J; Noer, I; Nørgaard, JP; Olesen, S; Rasmussen, PC; Wolf, H, 1994) |
| "To evaluate the efficacy and tolerability of doxazosin in the treatment of bladder outflow obstruction resulting from benign prostatic hyperplasia (BPH)." | 5.07 | A three month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction. ( Abrams, P; Bryan, J; Carter, P; Chapple, CR; Christmas, TJ; Kirby, RS; Milroy, EJ, 1994) |
| "The purpose of this single blind study was to verify the efficiency of Doxazosin Mesylate, an alpha-1 adrenergic blocker, in patients with benign prostatic hyperplasia (BPH)." | 5.07 | [Single-blind study of the effect of doxazosin mesylate in benign prostatic hypertrophy]. ( Belgrano, E; Deriu, M; Paoni, A; Siracusano, S; Tomasi, PA; Trombetta, C, 1994) |
| "The safety and efficacy of the selective alpha 1-blocking agent doxazosin 4 mg once daily in the symptomatic treatment of benign prostatic hyperplasia were evaluated in a randomized, double-blind and placebo-controlled 9-week study of 100 patients." | 5.07 | Doxazosin treatment in patients with prostatic obstruction. A double-blind placebo-controlled study. ( Bendix Holme, J; Christensen, MM; Husted, SE; Jacobsen, F; Nielsen, J; Noer, I; Nørgaard, JP; Olesen, S; Rasmussen, PC; Wolf, H, 1993) |
| "To assess the mechanistic relationship between doxazosin (alpha(1)-receptor antagonist) and receptor occupancy and a measure of pharmacological effect (Q(max), the maximum urinary flow rate) and to compare the mean receptor occupancy ratio at clinical doses of doxazosin, tamsulosin, terazosin and prazosin in benign prostatic hyperplasia (BPH)." | 4.84 | Assessment of alpha1-adrenoceptor antagonists in benign prostatic hyperplasia based on the receptor occupancy theory. ( Ito, K; Ohtani, H; Sawada, Y, 2007) |
| "alpha(1)-Adrenoceptor antagonists such as alfuzosin, doxazosin, tamsulosin and terazosin are first-line agents for the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia (BPH), but are only second-line agents (doxazosin and terazosin only) for the treatment of arterial hypertension." | 4.83 | Effects of alpha(1)-adrenoceptor antagonists on male sexual function. ( de la Rosette, JJ; Michel, MC; van Dijk, MM, 2006) |
| "Doxazosin is an effective treatment for patients with hypertension, benign prostatic hyperplasia (BPH) and the two comorbidly." | 4.82 | Effect of doxazosin GITS on blood pressure in hypertensive and normotensive patients: a review of hypertension and BPH studies. ( Kirby, RS; Lund-Johansen, P, 2003) |
| " Two studies, a placebo-controlled, double-blind trial (n = 70) and a community-based, open-label trial (n = 491) investigated the antihypertensive efficacy of doxazosin, a long-acting selective alpha1-adrenoceptor blocker, as add-on therapy for uncontrolled hypertension with other antihypertensive medications and in patients with concomitant benign prostatic hyperplasia (BPH) and treated but inadequately controlled hypertension, respectively." | 4.82 | Patients with uncontrolled hypertension or concomitant hypertension and benign prostatic hyperplasia. ( Zusman, R, 2004) |
| "Clinical studies have demonstrated that doxazosin therapy reduced blood pressure (BP) in patients with benign prostatic hyperplasia (BPH) who were hypertensive at baseline but not in patients who were physiologically or pharmacologically normotensive at baseline." | 4.82 | Clinical ease of using doxazosin in BPH patients with and without hypertension. ( Kirby, RS; Steers, WD, 2005) |
| "Doxazosin, a well established treatment in patients with bothersome lower urinary tract symptoms from benign prostatic hyperplasia (BPH), is available in a new controlled-release formulation, doxazosin gastrointestinal therapeutic system (GITS)." | 4.82 | Doxazosin gastrointestinal therapeutic system: a review of its use in benign prostatic hyperplasia. ( Goldsmith, DR; Plosker, GL, 2005) |
| "The combination of finasteride and doxazosin is cost-effective compared with dutasteride, tamsulosin, terazosin, and alfuzosin in patients with benign prostatic hyperplasia with moderate or severe symptoms who are older than 40 years." | 3.88 | Cost-Effectiveness of Combination Therapy Versus Monotherapy in Benign Prostatic Hyperplasia: A Colombian Experience. ( Arenas-Duque, A; Garcia-Perdomo, HA; Guevara-Cuellar, CA; Parody-Rúa, E, 2018) |
| "Doxazosin (Doxa) is an α1-selective adrenergic receptor (ADR) antagonist widely used, alone or in combination, to treat high blood pressure, benign prostatic hyperplasia symptoms, and recently has been suggested as a potential drug for prostate cancer prevention/treatment." | 3.79 | Orally applied doxazosin disturbed testosterone homeostasis and changed the transcriptional profile of steroidogenic machinery, cAMP/cGMP signalling and adrenergic receptors in Leydig cells of adult rats. ( Andric, SA; Janjic, MM; Kostic, TS; Stojkov, NJ, 2013) |
| "The association between intraoperative floppy iris syndrome (IFIS) and tamsulosin has been well-described." | 3.79 | Intraoperative floppy iris syndrome (IFIS) in patients receiving tamsulosin or doxazosin-a UK-based comparison of incidence and complication rates. ( Al-Ahmar, B; Haridas, A; Hingorani, M; Syrimi, M, 2013) |
| "The treatment of benign prostatic hyperplasia can be accomplished by the use of different drugs including, doxazosin, an α-1 adrenergic antagonist, and finasteride (FIN), a 5-α reductase inhibitor." | 3.79 | Development of a doxazosin and finasteride transdermal system for combination therapy of benign prostatic hyperplasia. ( Abrahim-Vieira, B; Cabral, LM; De Sousa, VP; Do Carmo, FA; Lopes, M; Padula, C; Pupe, CG; Ribeiro, AJ; Rodrigues, CR; Santi, P; Veiga, F, 2013) |
| "Finasteride (Fin) and Doxazosin (Dox), alone or in combination, have been widely used in treatment of benign prostatic hyperplasia (BPH) symptoms and recently have been suggested as potential drugs for prostate cancer (PCa)prevention and treatment." | 3.76 | Combined effect of the finasteride and doxazosin on rat ventral prostate morphology and physiology. ( Acquaro, C; Carvalho, RF; Felisbino, SL; Justulin, LA; Silva, MD, 2010) |
| "(-)Doxazosin and (+/-)doxazosin were administered intragastrically to prostatic hyperplasia rats, induced by testosterone propionate for 4 weeks, and each experimental group contained 8 animals." | 3.75 | Effects of (-)doxazosin on histomorphologic and cell apoptotic changes of the hyperplastic prostate in castrated rats. ( Kang, YH; Ren, LM; Su, XH; Tian, HL; Zhao, D, 2009) |
| "To evaluate the influence of doxazosin and finasteride on histologic findings in benign prostatic hyperplasia accompanied by prostatitis, and to examine the factors related with prostate carcinogenesis." | 3.74 | Histologic influence of doxazosin and finasteride in benign prostatic hyperplasia accompanying chronic inflammation. ( Park, DS; Shim, JY, 2008) |
| "Doxazosin triggers apoptosis via an imprecisely defined receptor mechanism that is related to tumor necrosis factor receptors (TNFRs)." | 3.74 | The influence of alpha1-antagonist on the expression pattern of TNF receptor family in primary culture of prostate epithelial cells from BPH patients. ( Debski, R; Drewa, T; Misterek, B; Styczynski, J; Wolski, Z, 2008) |
| "We used cDNA microarray analysis to obtain insights into the mechanisms of action of doxazosin, an alpha(1)-adrenergic receptor antagonist used to treat benign prostatic hyperplasia (BPH)." | 3.73 | Molecular targets of doxazosin in human prostatic stromal cells. ( Brooks, JD; Lai, F; Nonn, L; Peehl, DM; Zhao, H, 2005) |
| "To assess the long-term efficacy and safety of extended-release doxazosin gastrointestinal therapeutic system (GITS) under routine clinical care conditions over 12 months in Korean men with benign prostatic hyperplasia (BPH) with and without coexisting hypertension." | 3.73 | Long-term follow-up study to evaluate the efficacy and safety of the doxazosin gastrointestinal therapeutic system in patients with benign prostatic hyperplasia with or without concomitant hypertension. ( Chung, BH; Hong, SJ, 2006) |
| "An open, non-comparative, multicenter study was performed to ascertain the prevalence in Spain of erectile dysfunction (ED) associated to benign prostatic hypertrophy (BPH), with moderate to severe urinary symptoms, and to confirm the improvement or disappearance of ED in response to treatment with 4 mg/day of Doxazosin." | 3.72 | [Treatment with Doxazosin in 3347 patients with lower urinary tract symptoms. Impact on sexual function. The impros study]. ( Castaño González, I; Hernández Fernández, C; Jara Rascón, J; Moncada Iribarren, I; Moralejo Gárate, M, 2004) |
| "The Proscar Long-Term Efficacy and Safety Study (PLESS) and the Medical Therapy of Prostatic Symptoms (MTOPS) study provide new evidence regarding the benefits of finasteride in the treatment of benign prostatic hyperplasia (BPH)." | 3.72 | An economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia. ( Bernard, L; Brisson, M; Hux, M; McDonald, H; Nickel, JC, 2004) |
| "To compare efficacy and tolerance of tonocardin (doxazosin) and omnik (tamsulosin) in the treatment of benign prostatic hyperplasia (BPH) in hypertensive patients." | 3.72 | [Use of alpha-adrenoblockers in therapy of benign prostatic hyperplasia in patients with arterial hypertension]. ( Mazo, EB; Shashin, MN, 2004) |
| " Because benign prostatic hyperplasia (BPH) can give rise to irritative (hypersensory) voiding patterns, we questioned whether the bladder urothelium from patients with BPH released more ATP during in vitro stretch and whether doxazosin, an alpha(1)-adrenoceptor blocker, affects this purinergic mechanism." | 3.71 | Effect of doxazosin on stretch-activated adenosine triphosphate release in bladder urothelial cells from patients with benign prostatic hyperplasia. ( Chai, TC; Jacobs, SC; MaLossi, J; Sun, Y, 2002) |
| "Treatment of benign prostatic hyperplasia (BPH) with nonselective alpha1 antagonists such as terazosin, doxazosin, and prazosin results in blood pressure reduction due to vasodilation." | 3.71 | Initiation of nonselective alpha1-antagonist therapy and occurrence of hypotension-related adverse events among men with benign prostatic hyperplasia: a retrospective cohort study. ( Chao, J; Chrischilles, E; Gilden, D; Kreder, KJ; Rubenstein, L; Shah, H, 2001) |
| "The aim of our study is to verify the effects of doxazosin on sexual function in patients with benign prostatic hyperplasia (BPH)." | 3.71 | Observational multicentric trial performed with doxazosin: evaluation of sexual effects on patients with diagnosed benign prostatic hyperplasia. ( Belgrano, E; Bonini, F; Carmignani, G; Catuogno, C; Corbu, C; De Rose, AF; Di Trapani, D; Fontana, D; Giglio, M; Maver, A; Mirone, V; Muzzonigro, G; Naselli, A; Traverso, P, 2002) |
| "The molecular mechanisms underlying the therapeutic effect of the alpha1 blocker, doxazosin, on benign prostatic hyperplasia (BPH) are poorly understood." | 3.70 | Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia. ( Alexander, R; Borkowski, A; Jacobs, SC; Kyprianou, N; Litvak, JP, 1998) |
| "Doxazosin, an alpha1-adrenergic antagonist, inhibits sympathetic contraction of prostatic stromal smooth muscle cells and is used in the relief of obstructive benign prostatic hyperplasia (BPH)." | 3.70 | Influence of the alpha1-adrenergic antagonist, doxazosin, on noradrenaline-induced modulation of cytoskeletal proteins in cultured hyperplastic prostatic stromal cells. ( Foster, CS; Ke, Y; Rhodes, NP; Smith, P, 1999) |
| "Recent evidence indicated that an alpha 1 blocker, doxazosin, induces prostate apoptosis in patients with benign prostatic hyperplasia (BPH)." | 3.70 | Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia. ( Borkowski, A; Chon, JK; Isaacs, JT; Jacobs, SC; Kyprianou, N; Partin, AW, 1999) |
| "To study the possible relationship between adrenergic activities and the pathogenesis of benign prostatic hyperplasia (BPH), we tested the effect of doxazosin, an alpha 1-adrenoceptor antagonist, on prostatic growth in vivo using a mouse model for BPH." | 3.69 | Transforming growth factor beta 1 transduced mouse prostate reconstitutions: II. Induction of apoptosis by doxazosin. ( Park, SH; Thompson, TC; Timme, TL; Wu, X; Wyllie, MG; Yang, G, 1997) |
| "We investigate the results of ambulatory urodynamic evaluation of men with lower urinary tract symptoms (LUTS) believed secondary to benign prostatic hyperplasia (BPH) treated with doxazosin and compare these results to conventional urodynamic study." | 3.69 | Ambulatory urodynamic evaluation of men with lower urinary tract symptoms treated with doxazosin. ( Contreras, BA; Gerber, GS; Rukstalis, DB, 1997) |
| "To determine the safety and efficacy of alpha blockade with doxazosin and terazosin in men over the age of 80 years with symptomatic benign prostatic hyperplasia (BPH)." | 3.69 | The treatment of benign prostatic hyperplasia with alpha blockers in men over the age of 80 years. ( Ikeguchi, E; Kaplan, SA; Santarosa, RP; Te, AE, 1997) |
| " Alpha blockers in combination with muscarinic receptor antagonists may have the potential to improve symptoms." | 2.82 | A Randomized, Open-Label, Comparative Study of Efficacy and Safety of Tolterodine Combined with Tamsulosin or Doxazosin in Patients with Benign Prostatic Hyperplasia. ( Cao, Y; Chen, T; Guo, L; Niu, H; Wang, Y; Yang, X, 2016) |
| "Doxazosin and alfuzosin were both well tolerated, with most all-cause adverse events reported as mild or moderate." | 2.71 | Comparative efficacy of two alpha-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement. ( de Reijke, TM; Klarskov, P, 2004) |
| "Doxazosin is a potent reducer of the symptoms in the treatment of the BPE, enhancing urinary flow and reducing DCD in the first place." | 2.71 | [Analysis of doxazosin efficacy in the treatment of the benign prostatic enlargement]. ( Aganović, D; Aganović, K; Prcić, A, 2004) |
| "Few studies have reported the treatment of benign prostatic hyperplasia (BPH) in Asian patients." | 2.71 | Doxazosin for benign prostatic hyperplasia: an open-label, baseline-controlled study in Korean general practice. ( Chung, BH; Hong, SJ; Lee, MS, 2005) |
| "Patients with symptomatic bladder outlet obstruction and moderately enlarged prostates can receive durable relief from finasteride." | 2.70 | Discontinuation of alpha-blockade after initial treatment with finasteride and doxazosin for bladder outlet obstruction. ( Baldwin, KC; Ginsberg, PC; Harkaway, RC, 2001) |
| "A total of 248 hypertensive patients 45 years old or older with benign prostatic hyperplasia (BPH) was included in this 16-week, multicenter, double-blind, placebo-controlled, parallel-group dose-response study." | 2.68 | Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose-response multicenter study. ( Chrysant, SG; Conn, RL; Dias, N; Gaffney, M; Gillenwater, JY; Ice, K; Roy, J, 1995) |
| " Parameters evaluated included Boyarsky symptom score (Sx), peak uroflow (Qmax), blood pressure and occurrence of adverse events." | 2.68 | Terazosin and doxazosin in normotensive men with symptomatic prostatism: a pilot study to determine the effect of dosing regimen on efficacy and safety. ( Kaplan, SA; Olsson, CA; Soldo, KA, 1995) |
| "In this pilot study, the effect of dosing schedule on the efficacy and safety of the long-acting alpha 1-adrenergic blocker doxazosin (DOX) was evaluated in 48 consecutive, normotensive men (mean age, 61." | 2.67 | Effect of dosing regimen on efficacy and safety of doxazosin in normotensive men with symptomatic prostatism: a pilot study. ( Kaplan, SA; Olsson, CA; Soldo, KA, 1994) |
| "Several drugs, currently used to treat lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH), can be associated with bothersome sexual side effects, including ejaculatory dysfunction (EjD)." | 2.50 | Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis. ( Carini, M; Corona, G; Ficarra, V; Gacci, M; Maggi, M; Novara, G; Sebastianelli, A; Serni, S; Shariat, SF; Zattoni, F, 2014) |
| " α(1) Blockers generally lead to more adverse effects compared with placebo, and those caused by terazosin were more frequent than others." | 2.49 | The efficacy and safety of alpha-1 blockers for benign prostatic hyperplasia: an overview of 15 systematic reviews. ( Liu, Y; Mao, C; Qin, X; Yang, K; Yang, Z; Yuan, J, 2013) |
| "Both doxazosin and terazosin were significantly more likely than finasteride to improve peak urine flow and nocturia, versus finasteride." | 2.46 | Finasteride for benign prostatic hyperplasia. ( Fink, HA; Macdonald, R; Rutks, I; Tacklind, J; Wilt, TJ, 2010) |
| "Benign prostatic hyperplasia is an increasingly prevalent condition affecting > 50% of men > 65 years of age." | 2.44 | Finasteride and doxazosin alone or in combination for the treatment of benign prostatic hyperplasia. ( Bhardwa, J; Goldstraw, M; Kirby, R; Tzortzis, S, 2007) |
| "Secondary goal is inhibition of disease progression." | 2.44 | [Benign prostatic hyperplasia: medical therapy]. ( Gratzke, C; Reich, O; Schlenker, B; Seitz, M; Stief, CG; Weidlich, P, 2007) |
| "The therapeutic goal of treating benign prostatic hyperplasia (BPH) through early detection and effective therapy is to relieve the symptoms, improve patients' quality of life, decrease postvoid residual urine volume, and prevent the associated morbidity when the condition remains untreated." | 2.43 | The clinical efficacy and tolerability of doxazosin standard and gastrointestinal therapeutic system for benign prostatic hyperplasia. ( Desgrandchamps, F; Fitzpatrick, JM, 2005) |
| "The prevalence of benign prostatic hypertrophy (BPH) and erectile dysfunction (ED) both increase with age, and increasing evidence suggests a common cause rather than independent age-related changes." | 2.43 | Beneficial effects of extended-release doxazosin and doxazosin standard on sexual health. ( DE Rose, AF; Kaplan, SA; Kirby, RS; McVary, KT; O'leary, MP, 2006) |
| "Medical treatment for benign prostatic hyperplasia is reviewed by the author." | 2.42 | [Pharmacologic treatment of benign prostatic hyperplasia]. ( Romics, I, 2003) |
| "Doxazosin mesylate is an alpha1-adrenoceptor antagonist that was used to treat hypertension until a major study (ALLHAT; Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial) showed that it increased the risk of progressing to heart failure." | 2.42 | After ALLHAT: doxazosin for the treatment of benign prostatic hyperplasia. ( Doggrell, SA, 2004) |
| "To evaluate the efficacy and adverse effects of doxazosin for treating lower urinary tract symptoms (LUTS) compatible with benign prostatic obstruction (BPO)." | 2.42 | Doxazosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects. ( Howe, RW; MacDonald, R; Wilt, TJ, 2004) |
| "Medical and surgical options for the treatment of benign prostatic hyperplasia have expanded in recent years." | 2.41 | Managing benign prostatic hyperplasia. ( Bahnson, RR; Dull, P; Reagan, RW, 2002) |
| "The prevalence of both benign prostatic hyperplasia (BPH) and hypertension increases with advancing age." | 2.41 | The effect of doxazosin on sexual function in patients with benign prostatic hyperplasia, hypertension, or both. ( Flack, JM, 2002) |
| "dizziness and orthostatic hypotension)." | 2.40 | A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. ( Djavan, B; Marberger, M, 1999) |
| "Doxazosin is a long-acting alpha 1-adrenoceptor antagonist structurally related to prazosin and terazosin." | 2.39 | Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia. ( Fulton, B; Sorkin, EM; Wagstaff, AJ, 1995) |
| "Doxazosin is a selective alpha 1 antagonist with a long half-life and gradual onset of action, which make it suitable for once-daily treatment." | 2.39 | Profile of doxazosin in patients with benign prostatic hyperplasia. ( Janknegt, RA, 1995) |
| "Symptomatic benign prostatic hyperplasia (BPH) is a common condition in older men and has a significant impact on their daily lives." | 2.39 | Selective alpha 1-adrenoceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience. ( Chapple, CR, 1996) |
| " Frailty may contribute to both symptom progression and serious adverse events (SAEs), shifting the balance of benefits and harms of drug therapy." | 1.62 | Assessment of Frailty and Association With Progression of Benign Prostatic Hyperplasia Symptoms and Serious Adverse Events Among Men Using Drug Therapy. ( Bauer, SR; Covinsky, K; Ensrud, KE; Liu, TT; McVary, KT; Newman, JC; Ricke, WA; Suskind, AM; Walter, LC, 2021) |
| "From Feb 2011 to Jan 2012, 83 benign prostatic hyperplasia (BPH) patients with prostate volume (PV) >30 mL were enrolled in our study." | 1.43 | The new insight of prostate-specific antigen reduction during finasteride therapy in aging men. ( Ding, J; Duan, L; Qi, J; Qian, X; Xu, D; Zhu, Y, 2016) |
| "Determine if men with type 2 diabetes who take α-blockers (ABs) for benign prostatic hypertrophy gain additional benefit with reduced diabetic complications." | 1.42 | Effects of α-blocker therapy on active duty military and military retirees for benign prostatic hypertrophy on diabetic complications. ( Graybill, SD; Vigersky, RA, 2015) |
| "The standard gold care medications for benign prostatic hyperplasia (BPH) are the alpha-1-adrenergic antagonists, they are an effective medications and are generally well tolerated." | 1.40 | Alpha-1 adrenergic antagonists induced severe rhinitis in patients with benign prostatic hyperplasia. ( Hassoun, G; Kedem, E; Nassar, L; Shahar, E, 2014) |
| "Obesity was associated with increased prostate volume and lower urinary tract symptoms." | 1.37 | Comparison of the clinical efficacy of medical treatment of symptomatic benign prostatic hyperplasia between normal and obese patients. ( Chung, BH; Chung, MS; Lee, SH; Oh, CY; Park, KK; Yoo, SJ, 2011) |
| "Since trial results for benign prostatic hyperplasia phytotherapeutic agents are inconsistent, they may also be contaminated." | 1.36 | Investigating contamination of phytotherapy products for benign prostatic hyperplasia with alpha-blockers and 5alpha-reductase inhibitors. ( Adomat, H; Elterman, DS; Fleshner, N; Guns, E; Hersey, K; Lawrentschuk, N; Wood, CA, 2010) |
| "Doxazosin GITS treatment resulted in optimal management of BP within the normal range, especially in pharmacologically or physiologically hypertensive patients." | 1.36 | Effects of α-blocker 'add on' treatment on blood pressure in symptomatic BPH with or without concomitant hypertension. ( Chung, BH; Lee, SH; Mah, SY; Park, KK, 2010) |
| "Men participating in the 2001 and 2002 Prostate Cancer Awareness Week screening for prostate cancer were given a self-administered questionnaire." | 1.32 | Herbal and vitamin supplement use in a prostate cancer screening population. ( Barqawi, A; Crawford, ED; Gamito, E; O'Donnell, C, 2004) |
| "Benign prostate hyperplasia (BPH) and prostate cancer established that disruption of the molecular mechanisms that regulate apoptosis and cell proliferation among the stromal and epithelial cell populations, may underlie the neoplastic development that characterizes the aging gland." | 1.31 | Effects of alpha(1)-adrenoceptor (alpha(1)-AR) antagonists on cell proliferation and apoptosis in the prostate: therapeutic implications in prostatic disease. ( Benning, CM; Chon, J; Kyprianou, N, 2000) |
| "Doxazosin treatment resulted in improvements in both urodynamic and symptomatic parameters associated with BPH." | 1.29 | Efficacy and safety of the alpha-1 blocker doxazosin in the treatment of benign prostatic hyperplasia. Analysis of 5 studies. Doxazosin Study Groups. ( Chapple, CR; Janknegt, RA, 1993) |
| "Doxazosin has a slower onset of action and longer plasma half-life than any other available selective alpha 1-adrenoceptor inhibitor, which may confer advantages in terms of tolerability over the more rapidly absorbed and eliminated selective alpha 1-adrenoceptor inhibitors." | 1.29 | Profile of doxazosin in the hypertensive man with benign prostatic hyperplasia. ( Kirby, RS, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 63 (24.32) | 18.2507 |
| 2000's | 134 (51.74) | 29.6817 |
| 2010's | 55 (21.24) | 24.3611 |
| 2020's | 7 (2.70) | 2.80 |
| Authors | Studies |
|---|---|
| Kenny, B | 1 |
| Ballard, S | 1 |
| Blagg, J | 1 |
| Fox, D | 1 |
| Meyer, MD | 2 |
| Altenbach, RJ | 2 |
| Basha, FZ | 2 |
| Carroll, WA | 2 |
| Condon, S | 1 |
| Elmore, SW | 1 |
| Kerwin, JF | 3 |
| Sippy, KB | 2 |
| Tietje, K | 2 |
| Wendt, MD | 2 |
| Hancock, AA | 3 |
| Brune, ME | 3 |
| Buckner, SA | 3 |
| Drizin, I | 2 |
| Bai, H | 1 |
| Lebold, SA | 1 |
| Lee, E | 1 |
| Pratt, JK | 1 |
| Asfuroglu, A | 1 |
| Balci, M | 2 |
| Aslan, Y | 2 |
| Senel, C | 1 |
| Guzel, O | 2 |
| Kilinckaya, MF | 1 |
| Turhan, T | 1 |
| Tuncel, A | 2 |
| Bauer, SR | 1 |
| Walter, LC | 1 |
| Ensrud, KE | 1 |
| Suskind, AM | 1 |
| Newman, JC | 1 |
| Ricke, WA | 2 |
| Liu, TT | 1 |
| McVary, KT | 8 |
| Covinsky, K | 1 |
| Elbaz, R | 1 |
| El-Assmy, A | 1 |
| Zahran, MH | 1 |
| Hashem, A | 1 |
| Shokeir, AA | 1 |
| Mansbart, F | 1 |
| Kienberger, G | 1 |
| Sönnichsen, A | 1 |
| Mann, E | 1 |
| Pham, K | 1 |
| Ray, AW | 1 |
| Fernstrum, AJ | 1 |
| Alfahmy, A | 1 |
| Ray, S | 1 |
| Hijaz, AK | 1 |
| Ju, M | 1 |
| Sheyn, D | 1 |
| Ohyama, K | 1 |
| Hori, Y | 1 |
| Sugiura, M | 1 |
| Roehrborn, CG | 9 |
| Rukstalis, DB | 4 |
| Guo, J | 3 |
| Tang, R | 1 |
| Gupta, N | 1 |
| Rogers, T | 2 |
| Holland, B | 1 |
| Helo, S | 1 |
| Dynda, D | 1 |
| Wang, XP | 1 |
| Guevara-Cuellar, CA | 1 |
| Parody-Rúa, E | 1 |
| Garcia-Perdomo, HA | 1 |
| Arenas-Duque, A | 1 |
| Mahon, J | 1 |
| Gupta, NK | 1 |
| Song, CS | 2 |
| Zhao, JY | 2 |
| Chang, DG | 3 |
| Chen, L | 2 |
| Zhang, R | 2 |
| Wang, F | 2 |
| Macoska, JA | 1 |
| Uchtmann, KS | 1 |
| Leverson, GE | 1 |
| Lee, YC | 2 |
| Liu, CC | 2 |
| Juan, YS | 2 |
| Wu, WJ | 2 |
| Li, WM | 1 |
| Yeh, HC | 1 |
| Wang, CJ | 2 |
| Huang, CN | 2 |
| Huang, CH | 1 |
| Huang, SP | 2 |
| Stojkov, NJ | 1 |
| Janjic, MM | 1 |
| Kostic, TS | 1 |
| Andric, SA | 1 |
| Haridas, A | 1 |
| Syrimi, M | 1 |
| Al-Ahmar, B | 1 |
| Hingorani, M | 1 |
| Araki, T | 1 |
| Monden, K | 1 |
| Araki, M | 1 |
| Pupe, CG | 1 |
| Do Carmo, FA | 1 |
| De Sousa, VP | 1 |
| Lopes, M | 1 |
| Abrahim-Vieira, B | 1 |
| Ribeiro, AJ | 1 |
| Veiga, F | 1 |
| Rodrigues, CR | 1 |
| Padula, C | 1 |
| Santi, P | 1 |
| Cabral, LM | 1 |
| Lin, VC | 2 |
| Liao, CH | 3 |
| Wang, CC | 1 |
| Kuo, HC | 4 |
| Jhang, JF | 1 |
| Jiang, YH | 2 |
| Zisman, A | 1 |
| Fwu, CW | 2 |
| Eggers, PW | 2 |
| Kirkali, Z | 2 |
| Burrows, PK | 2 |
| Kusek, JW | 8 |
| Wang, YY | 1 |
| Shi, GW | 1 |
| He, JY | 1 |
| Zhang, YB | 1 |
| Tarhan, F | 1 |
| Çelik, O | 1 |
| Tosun, Ç | 1 |
| Faydacı, G | 1 |
| Eryıldırım, B | 1 |
| Gacci, M | 1 |
| Ficarra, V | 1 |
| Sebastianelli, A | 1 |
| Corona, G | 1 |
| Serni, S | 1 |
| Shariat, SF | 1 |
| Maggi, M | 1 |
| Zattoni, F | 1 |
| Carini, M | 1 |
| Novara, G | 1 |
| Shahar, E | 1 |
| Nassar, L | 1 |
| Kedem, E | 1 |
| Hassoun, G | 1 |
| Zhang, Q | 1 |
| Keten, T | 1 |
| Bilgin, O | 1 |
| Dilmen, C | 1 |
| Ozdemir, U | 1 |
| Yahsi, S | 1 |
| Atan, A | 2 |
| Graybill, SD | 1 |
| Vigersky, RA | 1 |
| Li, GS | 1 |
| Peng, CH | 1 |
| Yu, XJ | 1 |
| Zhang, PH | 1 |
| Bi, MS | 1 |
| Chen, DA | 1 |
| You, YD | 1 |
| Yang, XZ | 1 |
| Barkin, J | 1 |
| Diles, D | 1 |
| Franks, B | 1 |
| Berner, T | 1 |
| Kaplan, SA | 15 |
| Lee, JY | 4 |
| Meehan, AG | 4 |
| Xu, D | 1 |
| Ding, J | 1 |
| Zhu, Y | 2 |
| Qian, X | 1 |
| Duan, L | 1 |
| Qi, J | 2 |
| Bao, BY | 1 |
| Cao, Y | 1 |
| Wang, Y | 2 |
| Guo, L | 1 |
| Yang, X | 1 |
| Chen, T | 1 |
| Niu, H | 1 |
| Belayneh, M | 1 |
| Korownyk, C | 1 |
| Kirpatovskii, VI | 1 |
| Mudraya, IS | 1 |
| Revenko, SV | 1 |
| Bablumyan, AY | 1 |
| Adamyan, NK | 1 |
| Ivanov, VP | 1 |
| Liu, Q | 1 |
| Liu, J | 1 |
| Kang, J | 1 |
| Arikan, G | 1 |
| Demir, O | 3 |
| Yaman, A | 1 |
| Bozkurt, O | 3 |
| Saatci, AO | 1 |
| Durak, I | 1 |
| Esen, A | 1 |
| Mamalis, N | 1 |
| Il'nitskiĭ, AN | 2 |
| Proshchaev, KI | 2 |
| Filippov, SR | 1 |
| Liutsko, VV | 2 |
| Slikin, VV | 1 |
| Andersson, KE | 1 |
| Ng, CF | 1 |
| Wong, A | 1 |
| Cheng, CW | 1 |
| Chan, ES | 1 |
| Wong, HM | 1 |
| Hou, SM | 1 |
| McConnell, JD | 4 |
| Surynawanshi, S | 1 |
| Rotonda, J | 1 |
| Nyberg, LM | 5 |
| Prieto, L | 1 |
| Romero, J | 1 |
| López, C | 1 |
| Ortiz, M | 1 |
| Pacheco, JJ | 1 |
| Bar-Yosef, Y | 1 |
| Mabjeesh, NJ | 1 |
| Laufer, M | 1 |
| Neulander, EZ | 1 |
| Kaver, I | 1 |
| Matzkin, H | 1 |
| Slivkin, VV | 1 |
| Filippov, SV | 1 |
| Gileva, VV | 1 |
| Park, DS | 2 |
| Shim, JY | 1 |
| Justulin, LA | 1 |
| Acquaro, C | 1 |
| Carvalho, RF | 1 |
| Silva, MD | 1 |
| Felisbino, SL | 1 |
| Ozdemir, I | 2 |
| Aslan, G | 2 |
| Esen, AA | 2 |
| Tian, HL | 1 |
| Zhao, D | 1 |
| Ren, LM | 1 |
| Su, XH | 1 |
| Kang, YH | 1 |
| Zhang, Y | 2 |
| Zhang, P | 2 |
| Zhang, XD | 2 |
| Yang, Y | 3 |
| Elterman, DS | 1 |
| Lawrentschuk, N | 1 |
| Guns, E | 1 |
| Hersey, K | 1 |
| Adomat, H | 1 |
| Wood, CA | 1 |
| Fleshner, N | 1 |
| Fornari, A | 1 |
| Rhoden, EL | 1 |
| Zettler, CG | 1 |
| Ribeiro, EP | 1 |
| Rhoden, CR | 1 |
| Lavallée, LT | 1 |
| Dahm, P | 1 |
| Breau, RH | 1 |
| Lee, SH | 3 |
| Park, KK | 3 |
| Mah, SY | 1 |
| Chung, BH | 5 |
| Tacklind, J | 1 |
| Fink, HA | 1 |
| Macdonald, R | 3 |
| Rutks, I | 1 |
| Wilt, TJ | 3 |
| Sun, GH | 1 |
| Tsui, KH | 1 |
| Wu, TT | 1 |
| Chang, CH | 1 |
| Cheng, CL | 1 |
| Schou, M | 1 |
| Wu, ZJ | 1 |
| Huang, SY | 1 |
| Zhu, SX | 1 |
| Zeng, BW | 1 |
| Zhu, DS | 1 |
| Fang, RJ | 1 |
| Xiao, H | 1 |
| Li, HZ | 1 |
| Huang, ZM | 1 |
| Li, YQ | 1 |
| Alan, C | 1 |
| Kırılmaz, B | 1 |
| Koçoğlu, H | 1 |
| Ersay, AR | 1 |
| Ertung, Y | 1 |
| Eren, AE | 1 |
| Krome, S | 1 |
| Oh, CY | 1 |
| Chung, MS | 2 |
| Yoo, SJ | 2 |
| Jin, Z | 1 |
| Zhang, ZC | 1 |
| Liu, JH | 1 |
| Lu, J | 1 |
| Tang, YX | 1 |
| Sun, XZ | 1 |
| Song, WD | 1 |
| Gao, B | 1 |
| Guo, YL | 1 |
| Xin, ZC | 1 |
| Zhang, K | 1 |
| Yu, W | 1 |
| Jin, J | 2 |
| Ye, H | 1 |
| Wang, X | 1 |
| Zhang, N | 1 |
| Zhong, C | 1 |
| Wan, B | 1 |
| Sherman, JJ | 1 |
| Welch, RW | 1 |
| Hill, TM | 1 |
| McEwen, C | 1 |
| Goldfischer, E | 1 |
| Kowalczyk, JJ | 1 |
| Clark, WR | 1 |
| Brady, E | 1 |
| Shane, MA | 1 |
| Dgetluck, N | 1 |
| Klise, SR | 1 |
| Yuan, J | 1 |
| Liu, Y | 1 |
| Yang, Z | 1 |
| Qin, X | 1 |
| Yang, K | 1 |
| Mao, C | 1 |
| Dull, P | 1 |
| Reagan, RW | 1 |
| Bahnson, RR | 1 |
| Sun, Y | 1 |
| MaLossi, J | 1 |
| Jacobs, SC | 5 |
| Chai, TC | 1 |
| Pool, JL | 1 |
| Kirby, RS | 18 |
| Flack, JM | 1 |
| Erdoğru, T | 1 |
| Ciftcioglu, MA | 1 |
| Emreoglu, I | 1 |
| Usta, MF | 1 |
| Koksal, T | 1 |
| Ozbilim, G | 1 |
| Gulkesen, KH | 1 |
| Baykara, M | 1 |
| Takao, T | 1 |
| Tsujimura, A | 1 |
| Coetzee, S | 1 |
| Salm, SN | 1 |
| Lepor, H | 4 |
| Shapiro, E | 1 |
| Moscatelli, D | 1 |
| Wilson, EL | 1 |
| Roehrborn, C | 1 |
| Boyle, P | 1 |
| Bartsch, G | 2 |
| Jardin, A | 1 |
| Cary, MM | 1 |
| Sweeney, M | 1 |
| Grossman, EB | 1 |
| Doherty, AP | 1 |
| Kyprianou, N | 6 |
| Ukhal', MI | 3 |
| Strashnyĭ, VV | 2 |
| Ukhal', GM | 2 |
| Shumilin, MV | 2 |
| O'Leary, MP | 4 |
| Lund-Johansen, P | 1 |
| Gonzalez, CM | 1 |
| Romics, I | 1 |
| Cam, K | 1 |
| Akman, Y | 1 |
| Kayikci, A | 1 |
| Senel, F | 1 |
| Erol, A | 1 |
| Bautista, OM | 2 |
| Andriole, GL | 1 |
| Dixon, CM | 1 |
| Clarke, HS | 1 |
| Crawford, ED | 4 |
| Diokno, A | 1 |
| Foley, JP | 1 |
| Foster, HE | 1 |
| Kreder, KJ | 3 |
| Lieber, MM | 1 |
| Lucia, MS | 1 |
| Miller, GJ | 1 |
| Menon, M | 1 |
| Milam, DF | 1 |
| Ramsdell, JW | 1 |
| Schenkman, NS | 1 |
| Slawin, KM | 2 |
| Smith, JA | 2 |
| Lohm, L | 1 |
| Lindh, E | 1 |
| Frösing, R | 1 |
| Järhult, B | 1 |
| Lindahl, SO | 1 |
| Nilsson, PM | 1 |
| Gustafsson, LL | 1 |
| Lujan, M | 1 |
| Ferruelo, A | 1 |
| Paez, A | 1 |
| Moreno, A | 1 |
| Berenguer, A | 1 |
| Barqawi, A | 1 |
| Gamito, E | 1 |
| O'Donnell, C | 1 |
| Zusman, R | 1 |
| Tahmatzopoulos, A | 1 |
| Quinn, S | 2 |
| Mallen, S | 2 |
| Jensen, D | 1 |
| Brown, GA | 1 |
| Sussman, DO | 1 |
| Lorente Garín, JA | 1 |
| Cañis Sánchez, D | 1 |
| Arango Toro, O | 1 |
| Bielsa Gali, O | 1 |
| Cortadellas Angel, R | 1 |
| Gelabert Mas, A | 1 |
| Verhamme, KM | 1 |
| Bosch, RJ | 1 |
| Sturkenboom, MC | 1 |
| de Reijke, TM | 1 |
| Klarskov, P | 1 |
| Fitzpatrick, JM | 2 |
| Doggrell, SA | 2 |
| Hernández Fernández, C | 1 |
| Moncada Iribarren, I | 1 |
| Jara Rascón, J | 1 |
| Castaño González, I | 1 |
| Moralejo Gárate, M | 1 |
| Samli, MM | 1 |
| Dincel, C | 1 |
| Dutkiewicz, S | 4 |
| Zhao, H | 1 |
| Lai, F | 1 |
| Nonn, L | 1 |
| Brooks, JD | 1 |
| Peehl, DM | 1 |
| McDonald, H | 1 |
| Hux, M | 1 |
| Brisson, M | 1 |
| Bernard, L | 1 |
| Nickel, JC | 1 |
| Hausmann, R | 1 |
| Thalmann, G | 1 |
| Reich, O | 2 |
| Steif, CG | 1 |
| Kim, HW | 1 |
| Lee, SJ | 1 |
| Koh, JS | 1 |
| Suh, HJ | 1 |
| Chancellor, MB | 1 |
| Aganović, D | 1 |
| Aganović, K | 1 |
| Prcić, A | 1 |
| Watson, V | 1 |
| Ryan, M | 1 |
| Brown, CT | 1 |
| Barnett, G | 1 |
| Ellis, BW | 1 |
| Emberton, M | 1 |
| Turner, K | 1 |
| McNeill, SA | 1 |
| Mazo, EB | 1 |
| Shashin, MN | 1 |
| Howe, RW | 1 |
| Wyllie, M | 1 |
| Carson, C | 1 |
| Gratzke, P | 2 |
| Desgrandchamps, F | 2 |
| Steers, WD | 1 |
| Hong, SJ | 2 |
| Lee, MS | 1 |
| Bozlu, M | 1 |
| Ulusoy, E | 1 |
| Cayan, S | 1 |
| Akbay, E | 2 |
| Görür, S | 1 |
| DiSantostefano, RL | 1 |
| Biddle, AK | 1 |
| Lavelle, JP | 1 |
| Minnery, CH | 1 |
| Getzenberg, RH | 1 |
| Prajsner, A | 1 |
| Kirby, R | 2 |
| Andersen, M | 3 |
| Wyllie, MG | 2 |
| Lee, KS | 1 |
| Choo, MS | 1 |
| Kim, DY | 1 |
| Kim, JC | 1 |
| Kim, HJ | 1 |
| Min, KS | 1 |
| Lee, JB | 1 |
| Jeong, HJ | 1 |
| Lee, T | 1 |
| Park, WH | 1 |
| Goldsmith, DR | 1 |
| Plosker, GL | 1 |
| Athanasopoulos, A | 1 |
| Perimenis, P | 1 |
| Hernandez, C | 1 |
| Duran, R | 1 |
| Jara, J | 1 |
| Castaño, I | 1 |
| Moralejo, M | 1 |
| Calò, LA | 1 |
| Pagnin, E | 1 |
| Davis, PA | 1 |
| Lodde, M | 1 |
| Mian, C | 1 |
| Semplicini, A | 1 |
| Pycha, A | 1 |
| Lee, MW | 1 |
| Noble, WR | 2 |
| Cheng, TO | 1 |
| Irani, J | 1 |
| DE Rose, AF | 2 |
| Wilson, SS | 1 |
| Lieber, MC | 1 |
| van Dijk, MM | 1 |
| de la Rosette, JJ | 1 |
| Michel, MC | 1 |
| Pompeo, AC | 1 |
| Rosenblatt, C | 1 |
| Bertero, E | 1 |
| DA Ros, CT | 1 |
| Cairoli, CE | 1 |
| Damião, R | 1 |
| Wroclawski, ER | 1 |
| Koff, WJ | 1 |
| Mesquita, F | 1 |
| Pinheiro, GE | 1 |
| Ito, K | 1 |
| Ohtani, H | 1 |
| Sawada, Y | 1 |
| Cho, TW | 1 |
| Lee, YK | 1 |
| Lee, YT | 1 |
| Hong, YK | 1 |
| Jang, WK | 1 |
| Rahardjo, D | 1 |
| Soebadi, DM | 1 |
| Sugandi, S | 1 |
| Birowo, P | 1 |
| Djati, W | 1 |
| Wahyudi, I | 1 |
| Llorente, C | 1 |
| Ruiz, M | 1 |
| Rejas Gutiérrez, J | 1 |
| Esteban, M | 1 |
| Villasante, F | 1 |
| Hareendran, A | 1 |
| Xue, Z | 1 |
| Ding, Q | 1 |
| He, Z | 1 |
| Wang, J | 1 |
| Xu, K | 1 |
| Azadzoi, KM | 1 |
| Herd, MK | 1 |
| Cheung, CM | 1 |
| Awan, MA | 1 |
| Peh, KK | 1 |
| Sandramouli, S | 1 |
| Drewa, T | 1 |
| Wolski, Z | 1 |
| Misterek, B | 1 |
| Debski, R | 1 |
| Styczynski, J | 1 |
| Bhardwa, J | 1 |
| Goldstraw, M | 1 |
| Tzortzis, S | 1 |
| Jewett, MA | 1 |
| Klotz, LH | 1 |
| Johnson, TM | 1 |
| Tenover, JL | 1 |
| Ullrich, PM | 1 |
| Lutgendorf, SK | 1 |
| Schlenker, B | 1 |
| Gratzke, C | 1 |
| Weidlich, P | 1 |
| Seitz, M | 1 |
| Stief, CG | 1 |
| Li, NC | 1 |
| Wu, SL | 1 |
| Qiu, SP | 1 |
| Kong, CZ | 1 |
| Song, YS | 1 |
| Ye, ZQ | 1 |
| Sun, G | 1 |
| Sun, YH | 1 |
| Sun, YC | 1 |
| Wang, XF | 1 |
| Na, YQ | 1 |
| Janknegt, RA | 4 |
| Chapple, CR | 4 |
| Rollema, HJ | 1 |
| Bendix Holme, J | 2 |
| Christensen, MM | 2 |
| Rasmussen, PC | 2 |
| Jacobsen, F | 2 |
| Nielsen, J | 2 |
| Nørgaard, JP | 2 |
| Olesen, S | 2 |
| Noer, I | 2 |
| Wolf, H | 2 |
| Elkjaer Husted, S | 1 |
| Carter, P | 1 |
| Christmas, TJ | 1 |
| Bryan, J | 1 |
| Milroy, EJ | 1 |
| Abrams, P | 2 |
| Soldo, KA | 3 |
| Olsson, CA | 2 |
| Siracusano, S | 1 |
| Paoni, A | 1 |
| Tomasi, PA | 1 |
| Deriu, M | 1 |
| Trombetta, C | 1 |
| Belgrano, E | 2 |
| Stockamp, K | 1 |
| Fulton, B | 1 |
| Wagstaff, AJ | 1 |
| Sorkin, EM | 1 |
| Fawzy, A | 4 |
| Braun, K | 1 |
| Lewis, GP | 1 |
| Gaffney, M | 4 |
| Ice, K | 3 |
| Dias, N | 4 |
| Gillenwater, JY | 1 |
| Conn, RL | 1 |
| Chrysant, SG | 1 |
| Roy, J | 1 |
| Meade-D'Alisera, P | 1 |
| Quiñones, S | 1 |
| Witeska, A | 2 |
| Husted, SE | 1 |
| Stepień, K | 1 |
| Feneley, MR | 1 |
| Dunsmuir, WD | 1 |
| Pearce, J | 1 |
| Gerber, GS | 4 |
| Kim, JH | 2 |
| Contreras, BA | 4 |
| Steinberg, GD | 2 |
| Siegel, RL | 2 |
| Klimberg, I | 1 |
| Mobley, DF | 1 |
| Frankel, S | 1 |
| Katwala, SP | 1 |
| Milicic, I | 1 |
| Ireland, LM | 1 |
| Zagaja, GP | 1 |
| Gómez Sancha, F | 1 |
| Fernández Arjona, M | 1 |
| Peinado Ibarra, F | 1 |
| Fernández Borrell, A | 1 |
| Mínguez Martínez, R | 1 |
| Pereira Sanz, I | 1 |
| Yang, G | 1 |
| Timme, TL | 1 |
| Park, SH | 1 |
| Wu, X | 1 |
| Thompson, TC | 1 |
| Te, AE | 2 |
| Ikeguchi, E | 1 |
| Santarosa, RP | 1 |
| Salinas Casado, J | 3 |
| Esteban Fuertes, M | 3 |
| Virseda Chamorro, M | 3 |
| Ramírez Fernández, JC | 3 |
| Salomón Moh'd, S | 3 |
| Luengo Alpuente, S | 3 |
| Resel Estévez, L | 3 |
| Başar, MM | 1 |
| Yildiz, M | 1 |
| Akalin, Z | 1 |
| Beduschi, R | 2 |
| Beduschi, MC | 2 |
| Oesterling, JE | 2 |
| Akan, H | 1 |
| Başar, M | 1 |
| Dalva, I | 1 |
| Başar, H | 1 |
| D'Alisera, PM | 1 |
| Litvak, JP | 1 |
| Borkowski, A | 2 |
| Alexander, R | 1 |
| Grzeszczak, W | 1 |
| Turner, CD | 1 |
| Kuznetsov, D | 1 |
| Papadakis, JA | 1 |
| Mikhailidis, DP | 1 |
| Vashi, V | 1 |
| Chung, M | 1 |
| Smith, P | 2 |
| Rhodes, NP | 2 |
| Ke, Y | 2 |
| Foster, CS | 2 |
| Malomuzh, OI | 1 |
| Chon, JK | 1 |
| Partin, AW | 1 |
| Isaacs, JT | 1 |
| Boesch, ST | 1 |
| Corvin, S | 1 |
| Zhang, J | 1 |
| Rogatsch, H | 1 |
| Klocker, H | 1 |
| Djavan, B | 1 |
| Marberger, M | 1 |
| Hendry, A | 1 |
| Cook, E | 1 |
| Gonzalez, F | 1 |
| MacDiarmid, SA | 1 |
| Emery, RT | 1 |
| Ferguson, SF | 1 |
| McGuirt-Franklin, R | 1 |
| McIntyre, WJ | 1 |
| Johnson, DE | 1 |
| Guthrie, RM | 1 |
| Ozbey, I | 1 |
| Aksoy, Y | 1 |
| Polat, O | 1 |
| Biçgi, O | 1 |
| Demirel, A | 1 |
| Okyar, G | 1 |
| Jansen, DJ | 1 |
| Resch, ND | 1 |
| Hoffman, RM | 1 |
| Stifelman, M | 1 |
| Avillo, C | 1 |
| Reis, RB | 1 |
| Clifford, GM | 1 |
| Farmer, RD | 1 |
| Dahlstrand, C | 2 |
| Høye, K | 2 |
| Chon, J | 1 |
| Benning, CM | 1 |
| Caprino, L | 1 |
| Blanchard, K | 1 |
| Hananel, A | 1 |
| Rutchik, S | 1 |
| Sullivan, J | 1 |
| Baldwin, KC | 2 |
| Ginsberg, PC | 2 |
| Harkaway, RC | 2 |
| Türkeri, LN | 1 |
| Ozyürek, M | 1 |
| Ersev, D | 1 |
| Akdaş, A | 1 |
| Costantino, G | 1 |
| Clementi, G | 1 |
| Matera, M | 1 |
| Chrischilles, E | 1 |
| Rubenstein, L | 1 |
| Chao, J | 1 |
| Gilden, D | 1 |
| Shah, H | 1 |
| Simon, HB | 1 |
| Dutkiewics, S | 1 |
| Batista-Miranda, JE | 1 |
| Diez, MD | 1 |
| Bertrán, PA | 1 |
| Villavicencio, H | 1 |
| Akduman, B | 1 |
| Carmignani, G | 1 |
| Corbu, C | 1 |
| Giglio, M | 1 |
| Traverso, P | 1 |
| Naselli, A | 1 |
| Catuogno, C | 1 |
| Fontana, D | 1 |
| Maver, A | 1 |
| Mirone, V | 1 |
| Muzzonigro, G | 1 |
| Di Trapani, D | 1 |
| Bonini, F | 1 |
| Mansoor, GA | 1 |
| Tendler, BE | 1 |
| Heinzl, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prophylactic Tamsulosin in Prevention of Post-operative Urinary Retention in Men After Transanal Endoscopic Microsurgery: A Multicenter Randomized, Double-blind, Placebo-controlled Clinical Trial[NCT03314025] | Phase 2 | 158 participants (Anticipated) | Interventional | 2017-10-06 | Recruiting | ||
| The Effects of Systemic Alfuzosin and Tamsulosin Hydrochloride on Choroidal Thickness and Pupil Diameter Sizes in Cases With Benign Prostatic Hyperplasia[NCT03144596] | Phase 4 | 63 participants (Actual) | Interventional | 2015-10-29 | Completed | ||
| COX-2 Inhibitor Reduces Serum PSA Levels Might Predict a Lower Risk of Prostatic Cancer in Men With LUTS/BPH With an Elevated PSA Level[NCT01678313] | Phase 2 | 140 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| The Effect of Traditional Chinese Medicine VGH-BPH1 on Patients With Benign Prostatic Hyperplasia: A Double-blinded Randomized Placebo-controlled Cross-over Study[NCT03829904] | Phase 1/Phase 2 | 23 participants (Actual) | Interventional | 2019-03-06 | Completed | ||
| Phase II, Randomized, Double-Blind, Placebo-Controlled Trial Investigating the Efficacy and Safety of Org 3236 Tablets in Men With Lower Urinary Tract Symptoms (LUTS) Suggestive of Benign Prostatic Hyperplasia (BPH)[NCT00651807] | Phase 2 | 16 participants (Actual) | Interventional | 2008-03-31 | Terminated (stopped due to Business Reasons) | ||
| Medical Therapy of Prostatic Symptoms[NCT00021814] | Phase 3 | 3,407 participants (Actual) | Interventional | 1995-12-31 | Completed | ||
| Urokinase Plasminogen Activator System in Benign Prostatic Hyperplasia: A Possible Marker of Progression and Response to Medical Therapy[NCT00407329] | 30 participants (Actual) | Observational | 2006-11-30 | Completed | |||
| Effects of TNF Blockade on Human BPH/LUTS[NCT06062875] | Phase 2 | 70 participants (Anticipated) | Interventional | 2024-01-01 | Not yet recruiting | ||
| 5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy[NCT04288427] | 120 participants (Anticipated) | Interventional | 2020-09-25 | Recruiting | |||
| Urinary Nerve Growth Factor as a Biomarker for Medical Treatment of Male Lower Urinary Tract Symptoms: A Pilot Trial[NCT01457573] | Phase 4 | 10 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| Antimuscarinics as the First-line Treatment for Male With International Prostate Symptom Score (IPSS) Voiding-to-storage Subscore Rati (IPSS-V/S)≤1-- A Prospective Randomized Study Comparing With α-blockers[NCT01661621] | Phase 4 | 395 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| Multicenter Randomized Open-labelled Trial Which Aims to Show Non-inferiority of Adverse Events Risk During the Maintenance of Oral-anticoagulation in the Surgery of Benign Prostatic Hypertrophy by Laser Photovaporization[NCT03297281] | 389 participants (Anticipated) | Interventional | 2017-10-30 | Recruiting | |||
| CSP #407 - Prostate Cancer Intervention Versus Observation Trial (PIVOT): A Randomized Trial Comparing Radical Prostatectomy Versus Palliative Expectant Management for the Treatment of Clinically Localized Prostate Cancer[NCT00007644] | Phase 3 | 731 participants (Actual) | Interventional | 1994-11-30 | Completed | ||
| Prospective Multicenter Open-label One Arm Trial Investigating a Pumpkin Seed, Isoflavonoid and Cranberry Mix in Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia[NCT04146103] | 163 participants (Actual) | Interventional | 2018-04-01 | Completed | |||
| Study of the Effectiveness and the Tolerance of Intraprostatic A-botulinic Toxin Injection, in the Treatment of Symptomatic Benign Prostate Hypertrophy.[NCT01275521] | Phase 3 | 127 participants (Actual) | Interventional | 2011-01-10 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Efficacy:~Change from Baseline in the International Prostate Symptom Score (IPSS) from baseline and 3 months The International Prostate Symptom Score (IPSS) is an 7 symptom questions including 4 voiding questions (IPSS Voiding), 3 storage questions (IPSS Storage) The symptom score have 6-point scale ranging from 0 Not at all to 5 Almost always.~Total IPSS score = IPSS voiding + IPSS Storage Rang = 0 to 35 (asymptomatic to very symptomatic). Mild = 0 to 7; Moderate = 8 to 19; Severe = 20 to 35~Change = Month 3 minus Baseline value" (NCT01678313)
Timeframe: Baseline and 3 months after initial treatment
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | 3 months | Change | |
| Control Group | 12.0 | 7.70 | -4.31 |
| Study Group | 13.1 | 6.45 | -6.63 |
"Efficacy:~Change from Baseline in the IPSS Storage from baseline and 3 months The IPSS subscore (IPSS Storage) is a 3 symptom questions. The symptom score have 6-point scale ranging from 0 Not at all to 5 Almost always. Each question is assigned points from 0 to 5 indicating increasing severity of the particular symptom.~The total IPSS Storage score can therefore range from 0 to 15 (asymptomatic to very symptomatic).~Change = Month 3 minus Baseline value" (NCT01678313)
Timeframe: Baseline and 3 months after initial treatment
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | 3 months | Change | |
| Control Group | 6.06 | 4.01 | -2.05 |
| Study Group | 5.59 | 3.09 | -2.5 |
"Efficacy:~Change from Baseline in the IPSS Voiding from baseline and 3 months. The IPSS subscore (IPSS Voiding) questionnaires is a 4 symptom questions. The symptom score have 6-point scale ranging from 0 Not at all to 5 Almost always. Each question is assigned points from 0 to 5 indicating increasing severity of the particular symptom.~The total IPSS Voiding score can therefore range from 0 to 20 (asymptomatic to very symptomatic).~Change = Month 3 minus Baseline value" (NCT01678313)
Timeframe: Baseline and 3 months after initial treatment
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | 3 months | Change | |
| Control Group | 5.54 | 3.45 | -2.09 |
| Study Group | 7.55 | 3.84 | -3.71 |
"Efficacy:~Change from Baseline in the maximum flow rate (Qmax) from baseline and 3 months Change = Month 3 minus Baseline value" (NCT01678313)
Timeframe: Baseline and 3 months after initial treatment
| Intervention | mL/s (Mean) | ||
|---|---|---|---|
| Baseline | 3 months | Change | |
| Control Group | 10.0 | 11.9 | 1.9 |
| Study Group | 12.2 | 12.2 | -0.09 |
"Efficacy:~Change from Baseline in the serum PSA level from baseline and 3 months Change = Month 3 minus Baseline value" (NCT01678313)
Timeframe: Baseline and 3 months after initial treatment
| Intervention | ng/mL (Mean) | ||
|---|---|---|---|
| Baseline | 3 months | Change | |
| Control Group | 15.2 | 13.5 | -1.70 |
| Study Group | 10.8 | 9.42 | -1.43 |
"Efficacy:~Change from Baseline in the Void Volume (VV) from baseline and 3 months Change = Month 3 minus Baseline value" (NCT01678313)
Timeframe: Baseline and 3 months after initial treatment
| Intervention | mL (Mean) | ||
|---|---|---|---|
| Baseline | 3 months | Change | |
| Control Group | 175 | 231 | 55.7 |
| Study Group | 259 | 227 | -32.3 |
The urinary growth factor (GF) to creatinine ratio may be potential biomarker for overactive bladder, based on published articles. Measuring the ratio at baseline and Month 3, comparing the difference after treatment with tamsulosin and solifenacin which may provide insight into how lower urinary tract symptoms in men progresses. (NCT01457573)
Timeframe: change from baseline score to Month 3
| Intervention | ratio (Mean) |
|---|---|
| Baseline Characteristics | -19.61 |
Urine sample tested for urinary Nerve Growth Factor (uNGF as measured in pg/mL), a small secreted protein in the bladder that supports bladder function regulation, at baseline (pre-dose) and week 12/Month 3 post-dose, after using daily tamsulosin and solifenacin. (NCT01457573)
Timeframe: Change from baseline to week 12 (3 months)
| Intervention | pg/ml (Mean) |
|---|---|
| Single Arm Receiving Tamsulosin 0.4 mg and Solifenacin 5 mg | -10.9 |
Change in the International Consultation on Incontinence Modular Questionnaire on lower urinary tract symptoms quality of life survey for men, self administered, compared to Month 1, Month 2, and Month 3, after exposure to tamsulosin and solifenacin. The survey scoring is zero to 182, with 182 being the most bothersome and 0 to 1 being the least bothersome. (NCT01457573)
Timeframe: Change from baseline to months 1, 2 and 3
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Change at Month 1 | Change at Month 2 | Change at Month 3 | |
| Single Arm Receiving Tamsulosin 0.4 mg and Solifenacin 5 mg | 34.60 | 38.30 | -9.00 |
Measuring change in the International Consultation on Incontinence Modular Questionnaire for male lower urinary tract symptoms through a self administered survey at baseline compared to Month 1, Month 2, and Month 3, after exposure to tamsulosin and solifenacin. The survey score is a zero to 182 range with 182 being the most bothersome and zero to one being the least bothersome. (NCT01457573)
Timeframe: Change from baseline to months 1, 2 and 3
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Change at Month 1 | Change at Month 2 | Change at Month 3 | |
| Single Arm Receiving Tamsulosin 0.4 mg and Solifenacin 5 mg | -22.40 | -22.20 | -29.8 |
The survey, IPSS-International Prostate Score Scale, survey responses measured 0-35, is collected at baseline compared to post dose survey response at Month 1, Month 2, and Month 3/Week12 post-dose. The lower the score is indicative of less or fewer urinary symptoms while 35 is consistent with more bothersome symptoms. (NCT01457573)
Timeframe: Change from baseline to months 1, 2 and 3
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Change at Month 1 | Change at Month 2 | Change at Month 3 | |
| Single Arm Receiving Tamsulosin 0.4 mg and Solifenacin 5 mg | -2.00 | -5.30 | -7.33 |
Urination flow rate (measured in milliliters per second) at baseline (pre-dose), and Month 1, Month 2, and Month 3/Week 12 pose-dosing with tamsulosin and solifenacin. An average maximum urinary flow rate in males is 21 ml/sec aged 14-45 years-old and 12 ml/sec in males aged 46-65 years-old. (NCT01457573)
Timeframe: Change from baseline to months 1, 2 and 3
| Intervention | ml/s (Mean) | ||
|---|---|---|---|
| Change at Month 1 | Change at Month 2 | Change at Month 3 | |
| Single Arm Receiving Tamsulosin 0.4 mg and Solifenacin 5 mg | -3.20 | -3.90 | -4.70 |
Change in the Perception of Bladder through a self administered survey at baseline compared to Month 1, Month 2, and Month 3, following exposure to tamsulosin and solifenacin. The survey score measures from zero to 6, with 6 being the most bothersome bladder symptoms and 0 to 1 being the least bothersome. (NCT01457573)
Timeframe: Change from baseline to months 1, 2 and 3
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Change at Month 1 | Change at Month 2 | Change at Month 3 | |
| Single Arm Receiving Tamsulosin 0.4 mg and Solifenacin 5 mg | 1.29 | 0.29 | 0.00 |
Urine sample tested for urinary post void residual (measured in mL) at baseline (pre-dose), Month 1 and Month 2and week 12/Month 3 post-dose, post dose w/tamsulosin and solifenacin. (NCT01457573)
Timeframe: Change from baseline to months 1, 2 and 3
| Intervention | ml (Mean) | ||
|---|---|---|---|
| Change at Month 1 | Change at Month 2 | Change at Month 3 | |
| Single Arm Receiving Tamsulosin 0.4 mg and Solifenacin 5 mg | -6.90 | -10.00 | -3.60 |
The Patient Perception of Urinary Urgency self administered survey score has a maximum score 4, zero to four, for how severe a patient describes their urinary voiding frequency. Four is the most bothersome score, 0 or 1 is the least bothersome. Pre-dose / baseline score is compared at Month 1, Month 2, and Month 3, after dosing with tamsulosin and solifenacin. (NCT01457573)
Timeframe: Change from baseline to months 1, 2 and 3
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Change at Month 1 | Change at Month 2 | Change at Month 3 | |
| Single Arm Receiving Tamsulosin 0.4 mg and Solifenacin 5 mg | 0.00 | 0.30 | 0 |
Assessing the change from baseline to Month 1/Week 4 and Month 2/Week 8, of the urinary growth factor (GF) to creatinine ratio in men, which may be potential biomarker for overactive bladder, based on published articles. Measuring the ratio at baseline compared to Month 1 and Month 2 may provide insight into how lower urinary tract symptoms in men progresses. (NCT01457573)
Timeframe: change from baseline score to Mo.1/Wk4 and Mo.2/Wk8 scores
| Intervention | ratio (Mean) | |
|---|---|---|
| Change at Month 1 | Change at Month 2 | |
| Baseline Characteristics | -21.85 | -20.56 |
Urine sample tested for urinary Nerve Growth Factor (uNGF as measured in pg/mL), a small secreted protein in the bladder that supports bladder function regulation, at baseline (pre-dose) compared to Month 1/Week 4 and Month 2/Week 8, post dosing with tamsulosin and solifenacin. (NCT01457573)
Timeframe: Change from baseline to Mo.1/Wk4 and Mo.2/Wk8
| Intervention | pg/ml (Mean) | |
|---|---|---|
| Change at Month 1 | Change at Month 2 | |
| Single Arm Receiving Tamsulosin 0.4 mg and Solifenacin 5 mg | 11.17 | 15.64 |
"Efficacy Using global response assessment (GRA) to compare the efficacy in Group 1 and Group 2 from baseline to 1month.~The global response assessment on a 6-point scale ranging from 1 No problems at all to 6 Many severe problems.~Changes of the global response assessment (GRA) improved or reduction by 1 points.~Change = Baseline minus Month 1 value~Safety:~Systemic adverse events such as difficult urination, dry mouth, dry eye, blurred vision, constipation, dizziness or general weakness" (NCT01661621)
Timeframe: 1 month after initial treatment
| Intervention | participants (Number) | |
|---|---|---|
| GRA≥1 | GRA<1 | |
| Group 1 | 89 | 27 |
| Group 2 | 218 | 61 |
"Efficacy:~Using the the the International Prostate Symptom Score (IPSS) quality of life (QoL) score to compare the efficacy in Group 1 and Group 2 from baseline to 1month.~The IPSS quality of life question score on a 7-point scale ranging from 0 Delighted to 6 Terrible.~IPSS-QoL ranges 0 to 6 (Delighted to Terrible)~Safety:~Systemic adverse events such as difficult urination, dry mouth, blurred vision, constipation, dry eye, dizziness, or general weakness" (NCT01661621)
Timeframe: Baseline and 1 month
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | 1 month | |
| Group 1 | 3.91 | 2.82 |
| Group 2 | 3.88 | 2.82 |
"Efficacy:~Using the total International Prostate Symptom Score (IPSS) to compare the efficacy in Group 1 and Group 2 from baseline to 1 month.~The International Prostate Symptom Score (IPSS) is an 7 symptom questions including 4 voiding questions (IPSS-voiding), 3 storage questions (IPSS-Storage) The symptom score have 6-point scale ranging from 0 Not at all to 5 Almost always.~Total IPSS score = IPSS-voiding + IPSS-Storage Rang = 0 to 35 (asymptomatic to very symptomatic). Mild = 0 to 7; Moderate = 8 to 19; Severe = 20 to 35~Safety:~Systemic adverse events such as difficult urination, dry mouth, blurred vision, constipation, dry eye, dizziness, or general weakness" (NCT01661621)
Timeframe: Baseline and 1 month
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | 1 month | |
| Group 1 | 14.8 | 11.2 |
| Group 2 | 18.0 | 10.8 |
"Efficacy:~Using the the IPSS subscore (IPSS Storage) to compare the efficacy in Group 1 and Group 2 from baseline to 1 month.~The IPSS subscore (IPSS Storage) is a 3 symptom questions. The symptom score have 6-point scale ranging from 0 Not at all to 5 Almost always. Each question is assigned points from 0 to 5 indicating increasing severity of the particular symptom.~The total IPSS Storage score can therefore range from 0 to 15 (asymptomatic to very symptomatic).~Safety:~Systemic adverse events such as difficult urination, dry mouth, blurred vision, constipation, dry eye, dizziness, or general weakness" (NCT01661621)
Timeframe: Baseline and 1 month
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | 1 month | |
| Group 1 | 9.51 | 6.40 |
| Group 2 | 5.70 | 4.31 |
"Efficacy:~Using the the IPSS subscore (IPSS Voiding) questionnaires to compare the efficacy in Group 1 and Group 2 from baseline to 1 month.~The IPSS subscore (IPSS Voiding) questionnaires is a 4 symptom questions. The symptom score have 6-point scale ranging from 0 Not at all to 5 Almost always. Each question is assigned points from 0 to 5 indicating increasing severity of the particular symptom.~The total IPSS Voiding score can therefore range from 0 to 20 (asymptomatic to very symptomatic).~Safety:~Systemic adverse events such as difficult urination, dry mouth, blurred vision, constipation, dry eye, dizziness, or general weakness" (NCT01661621)
Timeframe: Baseline and 1 month
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | 1 month | |
| Group 1 | 5.31 | 4.84 |
| Group 2 | 12.3 | 6.49 |
"Efficacy:~Net change used the the maximum flow rate (Qmax) in Group 1 and Group 2 from baseline to 1 month.~Safety:~Systemic adverse events such as difficult urination, dry mouth, blurred vision, constipation, dry eye, dizziness, or general weakness" (NCT01661621)
Timeframe: Baseline and 1 month
| Intervention | mL/s (Mean) | |
|---|---|---|
| Baseline | 1 month | |
| Group 1 | 13.1 | 13.6 |
| Group 2 | 11.4 | 13.6 |
"Efficacy:~Net change used the the postvoid residual volume (PVR) in Group 1 and Group 2 from baseline to 1 month.~Safety:~Systemic adverse events such as difficult urination, dry mouth, blurred vision, constipation, dry eye, dizziness, or general weakness" (NCT01661621)
Timeframe: Baseline and 1 month
| Intervention | mL (Mean) | |
|---|---|---|
| Baseline | 1 month | |
| Group 1 | 50.1 | 60.4 |
| Group 2 | 53.9 | 42.9 |
"Efficacy:~Net change used the the voided volume in Group 1 and Group 2 from baseline to 1 month.~Safety:~Systemic adverse events such as difficult urination, dry mouth, blurred vision, constipation, dry eye, dizziness, or general weakness" (NCT01661621)
Timeframe: Baseline and 1 month
| Intervention | mL (Mean) | |
|---|---|---|
| Baseline | 1 month | |
| Group 1 | 212.5 | 231.6 |
| Group 2 | 244.0 | 268.3 |
Number of deaths from any cause. (NCT00007644)
Timeframe: From date of randomization until date of death from any cause, assessed until end of study, up to 16 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Radical Prostatectomy | 171 |
| Watchful Waiting | 183 |
55 reviews available for doxazosin and Adenoma, Prostatic
| Article | Year |
|---|---|
Pharmacological options in the treatment of benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Animals; Binding, Competitive; Controlle | 1997 |
Efficacy and safety of adrenergic alpha-1 receptor antagonists in older adults: a systematic review and meta-analysis supporting the development of recommendations to reduce potentially inappropriate prescribing.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents | 2022 |
Efficacy and tolerability of doxazosin gastro-intestinal therapeutic system versus tamsulosin in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: A systematic review and meta-analysis.
Topics: Doxazosin; Humans; Lower Urinary Tract Symptoms; Male; Prostatic Hyperplasia; Tamsulosin; Treatment | 2021 |
[Therapeutic effects of α-adrenergic receptor antagonists on benign prostatic hyperplasia: A network meta-analysis].
Topics: Adrenergic alpha-Antagonists; Doxazosin; Humans; Indoles; Male; Network Meta-Analysis; Prostatic Hyp | 2018 |
Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis.
Topics: Adrenergic alpha-1 Receptor Antagonists; Azasteroids; Doxazosin; Dutasteride; Ejaculation; Finasteri | 2014 |
Treatment of lower urinary tract symptoms in benign prostatic hypertrophy with α-blockers.
Topics: Adrenergic alpha-Antagonists; Dizziness; Doxazosin; Humans; Hypotension; Lower Urinary Tract Symptom | 2016 |
[Alpha blockers in use for symptomatic benign prostatic hyperplasia--are all drugs born equal?].
Topics: Adrenergic alpha-Antagonists; Doxazosin; Evidence-Based Medicine; Humans; Male; Prazosin; Prostatic | 2008 |
Current role of alpha-blockers in the treatment of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Clinical Trials as Topic; Doxazosin; Drug Administration | 2008 |
Finasteride for benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Disease Progression; Doxazosin; Drug The | 2010 |
[How effective is finasteride?].
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Doxazosin; Drug Therapy, Comb | 2011 |
The efficacy and safety of alpha-1 blockers for benign prostatic hyperplasia: an overview of 15 systematic reviews.
Topics: Adrenergic alpha-1 Receptor Antagonists; Doxazosin; Humans; Male; Naphthalenes; Piperazines; Prostat | 2013 |
Managing benign prostatic hyperplasia.
Topics: Complementary Therapies; Doxazosin; Humans; Male; Palpation; Prostatectomy; Prostatic Hyperplasia; S | 2002 |
Clinical significance of alpha1-adrenoceptor selectivity in the management of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Blood-Brain Barrier; Doxazosin; Humans; Male; | 2001 |
The effect of doxazosin on sexual function in patients with benign prostatic hyperplasia, hypertension, or both.
Topics: Adrenergic alpha-Antagonists; Aged; Doxazosin; Erectile Dysfunction; Humans; Hypertension; Male; Mid | 2002 |
Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance.
Topics: Adrenergic alpha-Antagonists; Apoptosis; Doxazosin; Humans; Male; Prazosin; Prostate; Prostatic Hype | 2003 |
Effect of doxazosin GITS on blood pressure in hypertensive and normotensive patients: a review of hypertension and BPH studies.
Topics: Antihypertensive Agents; Clinical Trials as Topic; Delayed-Action Preparations; Doxazosin; Humans; H | 2003 |
The role of combination therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Disease Progression; Doxazosin; Drug The | 2003 |
[Pharmacologic treatment of benign prostatic hyperplasia].
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Doxazosin; Enzyme Inhibitors; Finasterid | 2003 |
Patients with uncontrolled hypertension or concomitant hypertension and benign prostatic hyperplasia.
Topics: Antihypertensive Agents; Clinical Trials as Topic; Doxazosin; Drug Therapy, Combination; Humans; Hyp | 2004 |
Apoptotic impact of alpha1-blockers on prostate cancer growth: a myth or an inviting reality?
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Apoptosis; Doxazosin; Humans; | 2004 |
After ALLHAT: doxazosin for the treatment of benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Clinical Trials as Topic; Doxazosin; Dru | 2004 |
Doxazosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects.
Topics: Adrenergic alpha-Antagonists; Aged; Cross-Over Studies; Doxazosin; Drug Combinations; Enzyme Inhibit | 2004 |
The clinical efficacy and tolerability of doxazosin standard and gastrointestinal therapeutic system for benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Clinical Trials as Topic; Delayed-Action Prep | 2005 |
Clinical ease of using doxazosin in BPH patients with and without hypertension.
Topics: Antihypertensive Agents; Clinical Trials as Topic; Doxazosin; Humans; Hypertension; Male; Prostatic | 2005 |
One drug fits all.
Topics: Adrenergic alpha-Antagonists; Doxazosin; Drug Combinations; Drug Industry; Drug Therapy, Combination | 2005 |
Doxazosin gastrointestinal therapeutic system: a review of its use in benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Delayed-Action Preparations; Doxazosin; Human | 2005 |
Efficacy of the combination of an alpha1-blocker with an anticholinergic agent in the treatment of lower urinary tract symptoms associated with bladder outlet obstruction.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Benzhydryl Compounds; Benzila | 2005 |
Beneficial effects of extended-release doxazosin and doxazosin standard on sexual health.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Delayed-Action Preparations; Doxazosin | 2006 |
Effects of alpha(1)-adrenoceptor antagonists on male sexual function.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic Antagonists; Adult; Aged; Doxazosin; Ejaculation | 2006 |
Treatment and pharmacologic management of BPH in the context of common comorbidities.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Azasteroids; Cardiovascular Diseases; Co | 2006 |
[The objective of medical treatment: relieve the symptoms or stop the course?].
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; C | 2006 |
Assessment of alpha1-adrenoceptor antagonists in benign prostatic hyperplasia based on the receptor occupancy theory.
Topics: Adrenergic alpha-Antagonists; Doxazosin; Humans; Male; Prostatic Hyperplasia; Receptors, Adrenergic; | 2007 |
Finasteride and doxazosin alone or in combination for the treatment of benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Aged; Doxazosin; Drug Therapy, Combinati | 2007 |
[Benign prostatic hyperplasia: medical therapy].
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Adrenergic alpha-Antagonists; Algorithms; Azasteroids; Diseas | 2007 |
Doxazosin in the treatment of benign prostatic hypertrophy: an update.
Topics: Adrenergic alpha-Antagonists; Doxazosin; Drug Combinations; Enzyme Inhibitors; Finasteride; Humans; | 2006 |
[Therapy of benign prostatic hyperplasia with alpha receptor blockers].
Topics: Adrenergic alpha-Antagonists; Doxazosin; Humans; Male; Prazosin; Prostatic Hyperplasia; Receptors, A | 1995 |
Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia.
Topics: Carbohydrate Metabolism; Cardiovascular Diseases; Dosage Forms; Doxazosin; Drug Evaluation; Heart Ve | 1995 |
Profile of doxazosin in patients with benign prostatic hyperplasia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Blood Pressure; Doxazosin; Humans; Hypertension; Male; Pros | 1995 |
Efficacy of doxazosin in normotensive and hypertensive patients with benign prostatic hyperplasia.
Topics: Aged; Blood Pressure; Doxazosin; Humans; Hypertension; Male; Middle Aged; Prostatic Hyperplasia; Uro | 1995 |
Perspectives on the management of benign prostatic hyperplasia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Blood Pressure; Doxazosin; Humans; Hypertension; Male; Pros | 1995 |
Selective alpha 1-adrenoceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience.
Topics: Adrenergic alpha-Antagonists; Blood Pressure; Clinical Trials as Topic; Doxazosin; Half-Life; Humans | 1996 |
Measures of Proscar, Hytrin, and Cardura side effects.
Topics: Adrenergic alpha-Antagonists; Doxazosin; Finasteride; Humans; Male; Prazosin; Prostatic Hyperplasia | 1997 |
[Alpha blockers in the treatment of benign hyperplasia of the prostate].
Topics: Adrenergic alpha-Antagonists; Doxazosin; Humans; Indoramin; Male; Phenoxybenzamine; Prazosin; Prosta | 1997 |
Benign prostatic hyperplasia: use of drug therapy in primary care.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Aged; Doxazosin; Drug Therapy, Combinati | 1998 |
Pharmacotherapy for benign prostatic hyperplasia--the potential for alpha 1-adrenoceptor subtype-specific blockade.
Topics: Adrenergic alpha-Antagonists; Clinical Trials as Topic; Doxazosin; Hormones; Humans; Male; Patient S | 1998 |
Alpha-blockade therapy for benign prostatic hyperplasia: from a nonselective to a more selective alpha1A-adrenergic antagonist.
Topics: Adrenergic alpha-Antagonists; Clinical Trials as Topic; Doxazosin; Humans; Male; Prazosin; Prostatic | 1998 |
[Use of doxazosin (Cardura-Pfizer), alpha 1-adrenoreceptor antagonist, in treatment of hypertension in patients with diabetes].
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Animals; Diabetic Angiopathies; Doxazosin; Humans; Hyperc | 1998 |
Expanding role of alpha adrenoceptor blockade in the treatment of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Blood Pressure; Doxazosin; Humans; Male; Patient Selection; Prostatic | 1998 |
A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Controlled Clinical Trials as Topic; Dizzines | 1999 |
Medical therapy for benign prostatic hyperplasia: a review of the literature.
Topics: Adrenergic alpha-Antagonists; Doxazosin; Finasteride; Humans; Indoramin; Male; Prazosin; Prostatic H | 2000 |
[Drugs for the treatment of benign prostatic hypertrophy].
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Aged; Androgen Antagonists; D | 2000 |
Quality-of-life assessment in patients with benign prostatic hyperplasia: effects of various interventions.
Topics: Doxazosin; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia; Quality of Life; Ran | 2001 |
Terazosin, doxazosin, and prazosin: current clinical experience.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Doxazosin; Humans; Male; Middle Aged; Prazosin; Prostatic | 2001 |
Induction of apoptosis in the prostate by alpha1-adrenoceptor antagonists: a novel effect of "old" drugs.
Topics: Adrenergic alpha-Antagonists; Apoptosis; Doxazosin; Humans; Male; Prazosin; Prostatic Hyperplasia; T | 2000 |
[Prostatic adenoma: new drugs, new surgical techniques].
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Androstenes; Azasteroids; Cystoscopes; D | 1992 |
90 trials available for doxazosin and Adenoma, Prostatic
| Article | Year |
|---|---|
Mirabegron for treatment of erectile dysfunction concomitant with lower urinary tract symptoms in patients with benign prostatic obstruction: A randomized controlled trial.
Topics: Acetanilides; Doxazosin; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Prostatic | 2022 |
Three-Year Treatment Outcomes of Water Vapor Thermal Therapy Compared to Doxazosin, Finasteride and Combination Drug Therapy in Men with Benign Prostatic Hyperplasia: Cohort Data from the MTOPS Trial.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Aged; Cystoscopy; Disease Pro | 2018 |
Is Sexual Function Better Preserved After Water Vapor Thermal Therapy or Medical Therapy for Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia?
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; | 2018 |
[Treatment of Benign Prostatic Hyperplasia by Longbishu Capsule Combined Doxazosin Mesylate Tablet].
Topics: Aged; Capsules; Doxazosin; Drugs, Chinese Herbal; Humans; Male; Prostatic Hyperplasia; Quality of Li | 2016 |
Prostate Transition Zone Fibrosis is Associated with Clinical Progression in the MTOPS Study.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Biopsy; Cohort Studies; Disea | 2019 |
Comparison of 7 α(1)-adrenoceptor antagonists in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia:a short-term crossover study.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Aged, 80 and over; Cross-Over Studies; Doxazos | 2013 |
Adding Cyclooxygenase-2 inhibitor to alpha blocker for patients with benign prostate hyperplasia and elevated serum prostate specific antigen could not improve prostate biopsy detection rate but improve lower urinary tract symptoms.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Biopsy; Celecoxib; Cyclooxygenase 2 Inhibitors | 2013 |
Progression of lower urinary tract symptoms after discontinuation of 1 medication from 2-year combined alpha-blocker and 5-alpha-reductase inhibitor therapy for benign prostatic hyperplasia in men--a randomized multicenter study.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Aged; Azasteroids; Disease Pr | 2014 |
Change in sexual function in men with lower urinary tract symptoms/benign prostatic hyperplasia associated with long-term treatment with doxazosin, finasteride and combined therapy.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Disease Progression; Dose-Res | 2014 |
[Cardura monotherapy versus combination therapy of cardura and tolterodine L-tartrate tablets for II° ? benign prostatic hyperplasia with overactive bladder].
Topics: Aged; Benzhydryl Compounds; Cresols; Doxazosin; Drug Therapy, Combination; Humans; Male; Middle Aged | 2013 |
Comparison of the efficacy of isosorbide mononitrate and doxazosin in the treatment of lower urinary tract symptoms and benign prostatic hyperplasia: a randomized clinical trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Doxazosin; Drug Administration Schedule; Humans; Isos | 2014 |
Effect of Longbishu capsule () plus doxazosin on benign prostatic hyperplasia: a randomized controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Double-Blind Method; Doxazosin; Drugs, Chinese Herbal; Huma | 2014 |
Determination of the efficiency of 8 mg doxazosin XL treatment in patients with an inadequate response to 4 mg doxazosin XL treatment for benign prostatic hyperplasia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Aged, 80 and over; Doxazosin; Humans; Male; Middle Ag | 2015 |
[Longbishu Capsule combined with mesylate doxazosin: an efficacious therapy for benign prostatic hyperplasia].
Topics: Adrenergic alpha-Antagonists; Capsules; Double-Blind Method; Doxazosin; Drug Therapy, Combination; D | 2015 |
Time Course of Incident Adverse Experiences Associated with Doxazosin, Finasteride and Combination Therapy in Men with Benign Prostatic Hyperplasia: The MTOPS Trial.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Doxazosin; Drug Therapy, Comb | 2016 |
A Randomized, Open-Label, Comparative Study of Efficacy and Safety of Tolterodine Combined with Tamsulosin or Doxazosin in Patients with Benign Prostatic Hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Doxazosin; Drug Therapy, Combination; Humans; Male; Middle Aged; | 2016 |
[Clinical and neuroimmunoendocrine effects of doxasosine in treatment of arterial hypertension accompanied by prostate benign hyperplasia in elderly people].
Topics: Adrenergic alpha-Antagonists; Aged; Dose-Response Relationship, Drug; Doxazosin; Follow-Up Studies; | 2008 |
Effect of vardenafil on blood pressure profile of patients with erectile dysfunction concomitantly treated with doxazosin gastrointestinal therapeutic system for benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Analysis of Variance; Blood Pressure; Cross-Over Studies; Double | 2008 |
Long-term treatment with finasteride results in a clinically significant reduction in total prostate volume compared to placebo over the full range of baseline prostate sizes in men enrolled in the MTOPS trial.
Topics: Adrenergic alpha-Antagonists; Aged; Doxazosin; Drug Therapy, Combination; Enzyme Inhibitors; Finaste | 2008 |
Efficacy of doxazosin in the treatment of acute urinary retention due to benign prostate hyperplasia.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Delayed-Action Preparations; D | 2008 |
Combination therapy with doxazosin and tenoxicam for the management of lower urinary tract symptoms.
Topics: Adrenergic alpha-Antagonists; Cyclooxygenase 2 Inhibitors; Doxazosin; Drug Therapy, Combination; Hum | 2009 |
The effect of alpha-blocker therapy on erectile functions in patients with lower urinary tract symptoms due to benign prostate hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Doxazosin; Erectile Dysfunction; Humans; Male; Middle Aged; Peni | 2009 |
Efficacy and safety of the doxazosin gastrointestinal therapeutic system for the treatment of benign prostate hyperplasia.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Delayed-Action Preparations; Doxazosin; Humans; Male | 2010 |
[Clinical efficacy of a short-term regimen of Cardura XL on lower urinary tract symptoms and international prognostic scoring system in the treatment of benign prostatic hyperplasia].
Topics: Aged; Aged, 80 and over; Doxazosin; Humans; Male; Middle Aged; Prospective Studies; Prostatic Hyperp | 2010 |
[Frusemide plus doxazosin therapy for nocturia in patients with BPH/LUTS].
Topics: Aged; Aged, 80 and over; Doxazosin; Furosemide; Humans; Male; Middle Aged; Nocturia; Prostatic Hyper | 2010 |
[Clinical effectiveness and safety of combined therapy with an alpha-blocker and an anticholinergic drug for patients with benign prostatic hyperplasia].
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Cholinergic Antagonists; Doxazosin; Drug Ther | 2010 |
An open, comparative, multicentre clinical study of combined oral therapy with sildenafil and doxazosin GITS for treating Chinese patients with erectile dysfunction and lower urinary tract symptoms secondary to benign prostatic hyperplasia.
Topics: Aged; Asian People; China; Doxazosin; Erectile Dysfunction; Humans; Male; Middle Aged; Piperazines; | 2011 |
Effect of doxazosin gastrointestinal therapeutic system 4 mg vs tamsulosin 0.2 mg on nocturia in Chinese men with lower urinary tract symptoms: a prospective, multicenter, randomized, open, parallel study.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Doxazosin; Humans; Male; Middle Aged; Nocturi | 2011 |
Comparative rapid onset of efficacy between doxazosin gastrointestinal therapeutic system and tamsulosin in patients with lower urinary tract symptoms from benign prostatic hyperplasia: a multicentre, prospective, randomised study.
Topics: Adrenergic alpha-1 Receptor Antagonists; Doxazosin; Humans; Lower Urinary Tract Symptoms; Male; Midd | 2011 |
Hemodynamic effects of once-daily tadalafil in men with signs and symptoms of benign prostatic hyperplasia on concomitant α1-adrenergic antagonist therapy: results of a multicenter randomized, double-blind, placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Carbolines; Double-Blind Method; Doxazosin; Hemodynam | 2012 |
Long-term effects of doxazosin, finasteride and combination therapy on quality of life in men with benign prostatic hyperplasia.
Topics: Administration, Oral; Aged; Confidence Intervals; Dose-Response Relationship, Drug; Double-Blind Met | 2013 |
Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Aged; Diuresis; Double-Blind Method; Dox | 2003 |
A randomized, double-blind crossover study of tamsulosin and controlled-release doxazosin in patients with benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Cross-Over Studies; Delayed-Action Preparatio | 2003 |
Short-term subjective efficacy of doxazosin in predicting probability of prostatectomy in the management of benign prostatic hyperplasia in patients with severe symptoms.
Topics: Adrenergic alpha-Antagonists; Aged; Doxazosin; Follow-Up Studies; Humans; Male; Middle Aged; Patient | 2003 |
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Analysis of Variance; Disease Progressio | 2003 |
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Analysis of Variance; Disease Progressio | 2003 |
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Analysis of Variance; Disease Progressio | 2003 |
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Analysis of Variance; Disease Progressio | 2003 |
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Analysis of Variance; Disease Progressio | 2003 |
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Analysis of Variance; Disease Progressio | 2003 |
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Analysis of Variance; Disease Progressio | 2003 |
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Analysis of Variance; Disease Progressio | 2003 |
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Analysis of Variance; Disease Progressio | 2003 |
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Analysis of Variance; Disease Progressio | 2003 |
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Analysis of Variance; Disease Progressio | 2003 |
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Analysis of Variance; Disease Progressio | 2003 |
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Analysis of Variance; Disease Progressio | 2003 |
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Analysis of Variance; Disease Progressio | 2003 |
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Analysis of Variance; Disease Progressio | 2003 |
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Analysis of Variance; Disease Progressio | 2003 |
Doxazosin controlled release vs tamsulosin in the management of benign prostatic hyperplasia: an efficacy analysis.
Topics: Adrenergic alpha-Antagonists; Aged; Cross-Over Studies; Delayed-Action Preparations; Double-Blind Me | 2004 |
[Doxazosin in the gastrointestinal therapeutic system (GITS) formulation and trial without catheter after acute urinary retention due to BPH. Dose increase action on recovery effect].
Topics: Acute Disease; Aged; Doxazosin; Humans; Male; Prospective Studies; Prostatic Hyperplasia; Urinary Ca | 2004 |
Comparative efficacy of two alpha-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement.
Topics: Adrenergic alpha-Antagonists; Double-Blind Method; Doxazosin; Drug Administration Schedule; Humans; | 2004 |
Combination of finasteride and doxazosin for the treatment of benign prostatic hyperplasia.
Topics: Clinical Trials as Topic; Doxazosin; Drug Administration Schedule; Drug Synergism; Drug Therapy, Com | 2004 |
Terazosin and doxazosin in the treatment of BPH: results of a randomized study with crossover in non-responders.
Topics: Adrenergic alpha-Antagonists; Aged; Cross-Over Studies; Doxazosin; Humans; Male; Middle Aged; Prazos | 2004 |
Long-term treatment with doxazosin in men with benign prostatic hyperplasia: 10-year follow-up.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Doxazosin; Follow-Up Studies; Humans; Male; M | 2004 |
[Analysis of doxazosin efficacy in the treatment of the benign prostatic enlargement].
Topics: Adrenergic alpha-Antagonists; Aged; Doxazosin; Humans; Male; Prostatic Hyperplasia; Urodynamics | 2004 |
Efficacy of extended-release doxazosin and doxazosin standard in patients with concomitant benign prostatic hyperplasia and sexual dysfunction.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Delayed-Action Preparations; Double-Blind Met | 2005 |
[Doxazosin in the gastrointestinal therapeutic system (GITS) and doxazosin standard in patients with benign prostatic hyperplasia. Double-blind trial of efficacy and tolerability].
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Double-Blind Method; Doxazosin; Humans; Male; | 2000 |
Doxazosin for benign prostatic hyperplasia: an open-label, baseline-controlled study in Korean general practice.
Topics: Adrenergic alpha-Antagonists; Age Factors; Aged; Dose-Response Relationship, Drug; Doxazosin; Drug A | 2005 |
A double-blind placebo-controlled study evaluating the onset of action of doxazosin gastrointestinal therapeutic system in the treatment of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Double-Blind Method; Doxazosin; Humans; Least | 2005 |
Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter st
Topics: Adrenergic alpha-Antagonists; Aged; Benzilates; Comorbidity; Delayed-Action Preparations; Doxazosin; | 2005 |
Controlled-release doxazosin in the treatment of benign prostatic hyperplasia.
Topics: Aged; Blood Pressure; Doxazosin; Humans; Hypertension; Male; Prostate-Specific Antigen; Prostatic Hy | 2005 |
Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater.
Topics: Aged; Doxazosin; Drug Therapy, Combination; Finasteride; Humans; Male; Middle Aged; Prostate; Prosta | 2006 |
Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater.
Topics: Aged; Doxazosin; Drug Therapy, Combination; Finasteride; Humans; Male; Middle Aged; Prostate; Prosta | 2006 |
Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater.
Topics: Aged; Doxazosin; Drug Therapy, Combination; Finasteride; Humans; Male; Middle Aged; Prostate; Prosta | 2006 |
Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater.
Topics: Aged; Doxazosin; Drug Therapy, Combination; Finasteride; Humans; Male; Middle Aged; Prostate; Prosta | 2006 |
Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo.
Topics: Adrenergic alpha-Antagonists; Disease Progression; Doxazosin; Enzyme Inhibitors; Finasteride; Humans | 2006 |
A randomised, double-blind study comparing the efficacy and tolerability of controlled-release doxazosin and tamsulosin in the treatment of benign prostatic hyperplasia in Brazil.
Topics: Adrenergic alpha-Antagonists; Aged; Delayed-Action Preparations; Double-Blind Method; Doxazosin; Dru | 2006 |
Evaluation of short term clinical effects and presumptive mechanism of botulinum toxin type A as a treatment modality of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Botulinum Toxins, Type A; Doxazosin; Drug The | 2006 |
Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Blood Pressure; Doxazosin; Heart Rate; Humans; Male; Middle Aged | 2006 |
Doxazosin gastrointestinal therapeutic system versus tamsulosin for the treatment of benign prostatic hyperplasia: a study in Chinese patients.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; China; Delayed-Action Preparations; Doxazosin | 2007 |
The effect of doxazosin, finasteride and combination therapy on nocturia in men with benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Dose-Response Relationship, Drug; Double-Blind Method; Doxazosin; Drug | 2007 |
[Comparison of different drugs on the treatment of benign prostate hyperplasia].
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Androstadienes; | 2007 |
29-week doxazosin treatment in patients with symptomatic benign prostatic hyperplasia. A double-blind placebo-controlled study.
Topics: Aged; Double-Blind Method; Doxazosin; Drug Administration Schedule; Follow-Up Studies; Humans; Long- | 1994 |
A three month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction.
Topics: Aged; Aged, 80 and over; Double-Blind Method; Doxazosin; Humans; Male; Middle Aged; Prostatic Hyperp | 1994 |
Effect of dosing regimen on efficacy and safety of doxazosin in normotensive men with symptomatic prostatism: a pilot study.
Topics: Aged; Blood Pressure; Doxazosin; Drug Administration Schedule; Humans; Male; Middle Aged; Pilot Proj | 1994 |
[Single-blind study of the effect of doxazosin mesylate in benign prostatic hypertrophy].
Topics: Aged; Aged, 80 and over; Analysis of Variance; Doxazosin; Humans; Male; Middle Aged; Prostatic Hyper | 1994 |
Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study.
Topics: Aged; Blood Pressure; Double-Blind Method; Doxazosin; Follow-Up Studies; Heart Rate; Humans; Male; M | 1995 |
Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose-response multicenter study.
Topics: Aged; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Doxazosin; Heart Rate; | 1995 |
Doxazosin in benign prostatic hyperplasia: effects on blood pressure and urinary flow in normotensive and hypertensive men.
Topics: Aged; Blood Pressure; Double-Blind Method; Doxazosin; Humans; Hypertension; Male; Prostatic Hyperpla | 1995 |
Doxazosin in physiologically and pharmacologically normotensive men with benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Blood Pressure; Doxazosin; Humans; Hypertension; Male; Middle Ag | 1995 |
Doxazosin--an alpha-1 receptor blocking agent in the long-term management of benign prostatic hyperplasia (Part One).
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Blood Pressure; Doxazosin; Humans; Male; Midd | 1995 |
Doxazosin treatment in patients with prostatic obstruction. A double-blind placebo-controlled study.
Topics: Aged; Dose-Response Relationship, Drug; Double-Blind Method; Doxazosin; Drug Administration Schedule | 1993 |
Terazosin and doxazosin in normotensive men with symptomatic prostatism: a pilot study to determine the effect of dosing regimen on efficacy and safety.
Topics: Adrenergic alpha-Antagonists; Aged; Blood Pressure; Doxazosin; Drug Administration Schedule; Humans; | 1995 |
Doxazosin--an alpha-1 receptor blocking agent in the long-term management of benign prostatic hyperplasia (BPH) (Part Two).
Topics: Acid Phosphatase; Adrenergic alpha-Antagonists; Creatinine; Doxazosin; Humans; Male; Prazosin; Prost | 1995 |
An observational urodynamic evaluation of men with lower urinary tract symptoms treated with doxazosin.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Doxazosin; Humans; Male; Middle Aged; Prostat | 1996 |
Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Double-Blind Method; Doxazosin; Humans; Male; | 1996 |
Doxazosin for benign prostatic hyperplasia: long-term efficacy and safety in hypertensive and normotensive patients. The Multicenter Study Group.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Doxazosin; Humans; Hypertension; Male; Middle Aged | 1997 |
Doxazosin in men with lower urinary tract symptoms: urodynamic evaluation at 15 months.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Doxazosin; Follow-Up Studies; Humans; Male; M | 1997 |
Urodynamic effects of doxazosin in men with lower urinary tract symptoms and benign prostatic obstruction. Results from three double-blind placebo-controlled studies.
Topics: Adrenergic alpha-Antagonists; Denmark; Double-Blind Method; Doxazosin; Humans; Hypertension; Male; N | 1997 |
The early effects of doxazosin on benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Doxazosin; Humans; Male; Middle Aged; Prostat | 1998 |
Tolerability of alpha-blockade with doxazosin as a therapeutic option for symptomatic benign prostatic hyperplasia in the elderly patient: a pooled analysis of seven double-blind, placebo-controlled studies.
Topics: Adrenergic alpha-Antagonists; Age Factors; Aged; Double-Blind Method; Doxazosin; Electrocardiography | 1998 |
Morning versus evening dosing with doxazosin in benign prostatic hyperplasia: pharmacokinetics, efficacy and safety.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Double-Blind Method; Doxazosin; Drug Administration Sched | 1998 |
Use of novel urodynamic parameters, detrusor contraction duration and detrusor contraction index, in men with lower urinary tract symptoms.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Doxazosin; Humans; Male; Middle Aged; Prospec | 1998 |
Clinical correlation of maximal urinary flow rate and plasma doxazosin concentrations in the treatment of benign prostatic hyperplasia. Multicenter Study Group.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Doub | 1999 |
[The use of the alpha 1-adrenoblocker doxazosin in the pharmacotherapy of disorders of urine outflow of spastic origin].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Delayed-Action Preparations; Doxazosin; Humans; Male; Midd | 1998 |
Long-term (4 year) efficacy and tolerability of doxazosin for the treatment of concurrent benign prostatic hyperplasia and hypertension.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Blood Pressure; Double-Blind Method; Doxazosin; Follow-Up | 1999 |
A randomized double-blind study assessing 4 versus 8 mg. doxazosin for benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Double-Blind Method; Doxazosin; Drug Prescriptions; Humans; Male | 1999 |
[The clinical and flowmetric results of the treatment of benign prostatic hyperplasia with doxazosin].
Topics: Adrenergic alpha-Antagonists; Aged; Chi-Square Distribution; Doxazosin; Humans; Male; Middle Aged; P | 1999 |
Effects of doxazosin in men with benign prostatic hyperplasia: urodynamic assessment.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Doxazosin; Humans; Male; Middle Aged; Prostat | 1999 |
[The effect of symptomatic therapy with the alpha 1-adrenoblocker Cardura in patients with benign prostatic hyperplasia on the course of cardiovascular diseases].
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Cardiovascular Diseases | 1999 |
Double-blind trial of the efficacy and tolerability of doxazosin in the gastrointestinal therapeutic system, doxazosin standard, and placebo in patients with benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Delayed-Action Preparations; Digestive System | 2000 |
A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Delayed-Action Preparations; Double-Blind Met | 2001 |
Discontinuation of alpha-blockade after initial treatment with finasteride and doxazosin for bladder outlet obstruction.
Topics: Adrenergic alpha-Antagonists; Doxazosin; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyp | 2001 |
Apoptotic regression of prostatic tissue induced by short-term doxazosin treatment in benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Apoptosis; Double-Blind Method; Doxazosin; Humans; Male; Middle | 2001 |
[Long-term therapy of benign prostatic hyperplasia. Our experience].
Topics: Adrenergic alpha-Antagonists; Aged; Doxazosin; Finasteride; Follow-Up Studies; Humans; Male; Mepartr | 2001 |
Discontinuation of alpha-blockade after initial treatment with finasteride and doxazosin in men with lower urinary tract symptoms and clinical evidence of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Doxazosin; Drug Administration Schedule; Drug Therapy, Combinati | 2001 |
114 other studies available for doxazosin and Adenoma, Prostatic
| Article | Year |
|---|---|
Structure-activity studies for a novel series of tricyclic substituted hexahydrobenz[e]isoindole alpha(1A) adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia (BPH).
Topics: Adrenergic alpha-Antagonists; Animals; Blood Pressure; Cell Line; Dogs; Heterocyclic Compounds, 3-Ri | 2000 |
Structure-activity studies for a novel series of bicyclic substituted hexahydrobenz[e]isoindole alpha1A adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Cell Line; Dogs; Dox | 2001 |
What Is the Interaction between Urine C-Reactive Protein, Prostatic Inflammation, and Doxazosin Treatment in Patients with Benign Prostatic Hyperplasia? A Pilot Study.
Topics: Adrenergic alpha-Antagonists; Aged; C-Reactive Protein; Doxazosin; Humans; Inflammation; Male; Middl | 2022 |
Assessment of Frailty and Association With Progression of Benign Prostatic Hyperplasia Symptoms and Serious Adverse Events Among Men Using Drug Therapy.
Topics: Aged; Aged, 80 and over; Disease Progression; Doxazosin; Drug Therapy, Combination; Drug-Related Sid | 2021 |
Development of a machine learning-based predictive model for prediction of success or failure of medical management for benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Doxazosin; Drug Therapy, Combination; Finasteride; Humans; Machine Lea | 2023 |
Evaluation of syncope association with α
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Doxazosin; Humans; Hypertension; Indoles; Male; Midd | 2019 |
Prostatic Urethral Lift Versus Medical Therapy: Examining the Impact on Sexual Function in Men with Benign Prostatic Hyperplasia.
Topics: Doxazosin; Erectile Dysfunction; Finasteride; Humans; Male; Prostate; Prostatic Hyperplasia | 2022 |
Cost-Effectiveness of Combination Therapy Versus Monotherapy in Benign Prostatic Hyperplasia: A Colombian Experience.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Adult; Colombia; Cost-Benefit | 2018 |
The impact of metabolic syndrome on the responsiveness to α1-blocker in men with BPH/LUTS.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Aged, 80 and over; Doxazosin; Humans; Lower Ur | 2013 |
Orally applied doxazosin disturbed testosterone homeostasis and changed the transcriptional profile of steroidogenic machinery, cAMP/cGMP signalling and adrenergic receptors in Leydig cells of adult rats.
Topics: Adrenergic alpha-1 Receptor Antagonists; Androgens; Animals; Cells, Cultured; Cyclic AMP; Cyclic AMP | 2013 |
Intraoperative floppy iris syndrome (IFIS) in patients receiving tamsulosin or doxazosin-a UK-based comparison of incidence and complication rates.
Topics: Adrenergic alpha-1 Receptor Antagonists; Atropine; Doxazosin; Drug Therapy, Combination; Female; Hum | 2013 |
Development of a doxazosin and finasteride transdermal system for combination therapy of benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Administration, Cutaneous; Adrenergic alpha-1 Receptor Antagonists; An | 2013 |
5α-Reductase inhibitor is less effective in men with small prostate volume and low serum prostatic specific antigen level.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Biopsy; Chi-Squ | 2015 |
Editorial comment.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Azasteroids; Doxazosin; Dutas | 2014 |
How much improvement is needed for a real difference of lower urinary tract symptoms after long-term combination therapy for benign prostatic hyperplasia.
Topics: Azasteroids; Doxazosin; Drug Therapy, Combination; Humans; Lower Urinary Tract Symptoms; Male; Prost | 2014 |
Alpha-1 adrenergic antagonists induced severe rhinitis in patients with benign prostatic hyperplasia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Cerebrospinal Fluid Rhinorrhea; Doxazosin; Humans; Ma | 2014 |
Effects of α-blocker therapy on active duty military and military retirees for benign prostatic hypertrophy on diabetic complications.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Angiotensin Receptor Antagonists; Angiotensin- | 2015 |
Alpha blocker monotherapy versus combination therapy with antimuscarinics in men with persistent LUTS refractory to alpha-adrenergic treatment: patterns of persistence.
Topics: Administrative Claims, Healthcare; Adrenergic alpha-Antagonists; Aged; Benzofurans; Doxazosin; Drug | 2015 |
Re: Comparison of the Efficacy of Isosorbide Mononitrate and Doxazosin in the Treatment of Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia: A Randomized Clinical Trial.
Topics: Doxazosin; Humans; Isosorbide Dinitrate; Lower Urinary Tract Symptoms; Male; Prostatic Hyperplasia | 2015 |
The new insight of prostate-specific antigen reduction during finasteride therapy in aging men.
Topics: Aged; Asian People; Doxazosin; Finasteride; Follow-Up Studies; Humans; Male; Middle Aged; Prostate-S | 2016 |
The association of endothelial nitric oxide synthase (eNOS) G894T gene polymorphism with responsiveness to a selective α1 -blocker in men with benign prostatic hyperplasia related lower urinary tract symptoms.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Aged, 80 and over; Doxazosin; Humans; Lower Ur | 2016 |
Effect of Doxazosin on Autonomic Nervous Control and Urodynamics of Rat Urinary Bladder during Modeled Infravesical Obstruction.
Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Doxazosin; Drug Evaluation, Preclinical; Female; M | 2016 |
Ultrasound image features of intravesical prostatic protrusion indicated failure of medication therapy of finasteride and doxazosin in patients with benign prostatic hyperplasia (LUTS/BPH).
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Doxazosin; Drug Therapy, Combination; Finasteride; Hu | 2017 |
The effect of various alpha1-adrenergic receptor antagonists on pupillary dilation.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Doxazosin; Humans; Iris Disea | 2008 |
Intraoperative floppy-iris syndrome associated with systemic alpha blockers.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Cataract Extraction; Doxazosi | 2008 |
How many drugs for LUTS due to BPH are too many?
Topics: Adrenergic alpha-Antagonists; Benzhydryl Compounds; Cresols; Doxazosin; Drug Therapy, Combination; E | 2008 |
[Clinical and neuroimmunoendocrine effects of doxasosine in treatment of benign hyperplasia of the prostate in elderly people].
Topics: Adrenergic alpha-Antagonists; Aged; Aging; Cell Adhesion Molecules; Doxazosin; Humans; Interleukin-6 | 2008 |
Histologic influence of doxazosin and finasteride in benign prostatic hyperplasia accompanying chronic inflammation.
Topics: Aged; Aged, 80 and over; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antihypertensive A | 2008 |
Combined effect of the finasteride and doxazosin on rat ventral prostate morphology and physiology.
Topics: Androgens; Animals; Cell Proliferation; Dihydrotestosterone; Doxazosin; Epithelial Cells; Extracellu | 2010 |
Effects of (-)doxazosin on histomorphologic and cell apoptotic changes of the hyperplastic prostate in castrated rats.
Topics: Animals; Apoptosis; Doxazosin; Male; Prostatic Hyperplasia; Rats; Rats, Wistar; Testosterone Propion | 2009 |
When you just can't go: my patient, a 63-year old stockbroker, recalled his experience with acute urinary retention.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Doxazosin; Enzyme Inhibitors; Finasteride; Humans; Male | 2009 |
Extended-release doxazosin for treatment of renal transplant recipients with benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Blood Urea Nitrogen; Delayed-Action Preparations; Doxazosin; Fam | 2009 |
Investigating contamination of phytotherapy products for benign prostatic hyperplasia with alpha-blockers and 5alpha-reductase inhibitors.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Azasteroids; Capsules; Cholestenone 5 alpha-Redu | 2010 |
Effects of the chronic use of finasteride and doxazosin mesylate on the histomorphometric characteristics of the prostate: experimental study in rats.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Animals; Disease Models, Anim | 2011 |
Evidence-based urology in practice: composite endpoints.
Topics: 5-alpha Reductase Inhibitors; Doxazosin; Drug Therapy, Combination; Endpoint Determination; Evidence | 2010 |
Effects of α-blocker 'add on' treatment on blood pressure in symptomatic BPH with or without concomitant hypertension.
Topics: Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents; Blood Pressure; Doxazosin; Drug Combina | 2010 |
Comparison of effects of alpha receptor blockers on endothelial functions and coagulation parameters in patients with benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Blood Coagulation; Blood Pressure; Brachial Artery; Doxazosin; E | 2011 |
Comparison of the clinical efficacy of medical treatment of symptomatic benign prostatic hyperplasia between normal and obese patients.
Topics: Adrenergic alpha-1 Receptor Antagonists; Body Mass Index; Case-Control Studies; Doxazosin; Humans; M | 2011 |
Prescriber monitoring for benign prostatic hyperplasia within a family medicine clinic: a comparison of medication classes.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Aged; Doxazosin; Drug Therapy, Combinati | 2012 |
Effect of doxazosin on stretch-activated adenosine triphosphate release in bladder urothelial cells from patients with benign prostatic hyperplasia.
Topics: Adenosine Triphosphate; Adrenergic alpha-Antagonists; Doxazosin; Elasticity; Humans; Male; Prostatic | 2002 |
Two-drug therapy is best for symptomatic prostate enlargement: combination should change clinical practice.
Topics: Doxazosin; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Mul | 2002 |
Apoptotic and proliferative index after Alpha-1-adrenoceptor antagonist and/or finasteride treatment in benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combine | 2002 |
Stromal/epithelial interactions of murine prostatic cell lines in vivo: a model for benign prostatic hyperplasia and the effect of doxazosin on tissue size.
Topics: Adrenergic alpha-Antagonists; Animals; Cell Communication; Cell Line; Disease Models, Animal; Doxazo | 2003 |
[5-alpha reductase inhibitors or alpha blockers? The combination brakes best prostatic hyperplasia].
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Clinical Trials as Topic; Doxazosin; Dru | 2002 |
Second opinion. I have benign prostatic hyperplasia. The drug my doctor prescribed has helped somewhat, but I'm still making a lot of trips to the bathroom at night. Short of surgery, are there any new approaches to managing this condition that might be m
Topics: Adrenergic alpha-Antagonists; Doxazosin; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; | 2002 |
Benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Clinical Trials as Topic; Doxazosin; Drug Therapy, Combination; Enzyme | 2003 |
[The incidence, features of the course, and treatment of arterial hypertension in patients with prostate hyperplasia].
Topics: Adrenergic alpha-Antagonists; Aged; Blood Pressure; Diuresis; Doxazosin; Heart Rate; Humans; Hyperte | 2003 |
By the way, doctor. I'm 77 and have an enlarged prostate. I take Proscar once a day and saw palmetto three times a day. Yet I still have to get up two to seven times a night to urinate. What can I do to reduce the frequency of urination?
Topics: Adrenergic alpha-Antagonists; Aged; Doxazosin; Drug Therapy, Combination; Enzyme Inhibitors; Finaste | 2003 |
[5-alpha reductase inhibitors plus alpha blockers. A combination therapy keeps a common disease checked].
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Age Factors; Aged; Doxazosin; Drug Thera | 2003 |
[Benign prostatic syndrome. 3-step plan for the treatment].
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Clinical Trials as Topic; Doxazosin; Dru | 2003 |
[Alfadil and heart failure--clinical conclusions do exist!].
Topics: Anticholesteremic Agents; Antihypertensive Agents; Doxazosin; Drug Information Services; Heart Failu | 2003 |
[Two drugs have a better outcome. Finasteride plus alpha blocker improves urine flow].
Topics: Adrenergic alpha-Antagonists; Aged; Clinical Trials as Topic; Doxazosin; Drug Therapy, Combination; | 2003 |
[Doxazosin and heart failure: a clinical conclusion is wanted].
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Doxazosin; Heart Failure; Humans; Hypertensio | 2003 |
[ALLHAT--remaining questions await answers].
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Benzothiadiazines; Calcium Channel Blockers; | 2004 |
[Choice of antihypertensive agent--insignificant role of doxazosin (Alfadil). How are evidence-based recommendations implemented?].
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Contraindications; Doxazosin; Evidence-Based | 2004 |
Prostate apoptosis after doxazosin treatment in the spontaneous hypertensive rat model.
Topics: Analysis of Variance; Animals; Antihypertensive Agents; Apoptosis; Caspases; Cohort Studies; Doxazos | 2004 |
Herbal and vitamin supplement use in a prostate cancer screening population.
Topics: Adenocarcinoma; Adrenergic alpha-Antagonists; Adult; Aged; Colorado; Complementary Therapies; Dietar | 2004 |
Drug combo stalls BPH progression.
Topics: Adrenergic Antagonists; Doxazosin; Humans; Male; Prostatic Hyperplasia | 2004 |
A current review of medical therapy for benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Algorithms; Azasteroids; Cholestenone 5 alpha-Reductase; Doxazosin; Dr | 2004 |
Finasteride in benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Acute Disease; Adrenergic alpha-Antagonists; Cohort Studies; Doxazosin | 2004 |
Two-drug therapy is best for symptomatic prostate enlargement: could a combination of doxazosin and finasteride change clinical practice?
Topics: Adrenergic alpha-Antagonists; Doxazosin; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; | 2004 |
[Treatment with Doxazosin in 3347 patients with lower urinary tract symptoms. Impact on sexual function. The impros study].
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Doxazosin; Erectile Dysfunction; Human | 2004 |
Molecular targets of doxazosin in human prostatic stromal cells.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Apoptosis; Cell Proliferation; Doxazosin; Gene Expression | 2005 |
An economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Cost-Benefit Analysis; Doxazosin; Drug Therapy, Combination; Enzyme In | 2004 |
[Therapy of benign prostatic hyperplasia with finasteride and doxazosin -- long-term studies support the combination].
Topics: Adrenergic alpha-Antagonists; Controlled Clinical Trials as Topic; Disease Progression; Double-Blind | 2004 |
Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder.
Topics: Adrenergic alpha-Antagonists; Benzhydryl Compounds; Cresols; Doxazosin; Humans; Male; Middle Aged; P | 2004 |
Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder.
Topics: Adrenergic alpha-Antagonists; Benzhydryl Compounds; Cresols; Doxazosin; Humans; Male; Middle Aged; P | 2004 |
Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder.
Topics: Adrenergic alpha-Antagonists; Benzhydryl Compounds; Cresols; Doxazosin; Humans; Male; Middle Aged; P | 2004 |
Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder.
Topics: Adrenergic alpha-Antagonists; Benzhydryl Compounds; Cresols; Doxazosin; Humans; Male; Middle Aged; P | 2004 |
Eliciting preferences for drug treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Azasteroids; Doxazosin; Dutasteride; H | 2004 |
MTOPS: conclusions about invasive therapy for BPH should be interpreted with caution.
Topics: Adrenergic alpha-Antagonists; Doxazosin; Drug Therapy, Combination; Finasteride; Humans; Male; Prost | 2004 |
[Use of alpha-adrenoblockers in therapy of benign prostatic hyperplasia in patients with arterial hypertension].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Antineoplastic Agents | 2004 |
Blood pressure and urologists: like oil and water?
Topics: Blood Pressure; Doxazosin; Humans; Male; Prostatic Hyperplasia; Urinary Retention; Vasodilator Agent | 2004 |
Finasteride with doxazosin to reduce BPH progression.
Topics: Disease Progression; Doxazosin; Drug Therapy, Combination; Finasteride; Humans; Male; Prostatic Hype | 2005 |
A comparison of four different alpha1-blockers in benign prostatic hyperplasia patients with and without diabetes.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Cohort Studies; Diabetes Mellitus; Doxazosin; | 2004 |
Re: an economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Cost-Benefit Analysis; Doxazosin; Drug Therapy, Combination; Enzyme In | 2005 |
Benign prostatic hyperplasia cell line viability and modulation of jm-27 by doxazosin and Ibuprofen.
Topics: Adrenergic alpha-Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Antigens, Neoplasm; Cell Line | 2005 |
Long-term follow-up study to evaluate the efficacy and safety of the doxazosin gastrointestinal therapeutic system in patients with benign prostatic hyperplasia with or without concomitant hypertension.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Delayed-Action Preparations; Dose-Response | 2006 |
Effect of doxazosin on oxidative stress-related proteins in benign prostatic hyperplasia.
Topics: Aged; Aged, 80 and over; Doxazosin; Heat-Shock Proteins; Humans; Male; Middle Aged; Oxidative Stress | 2006 |
Should patients with benign prostatic hypertrophy stop taking doxazosin in the light of the ALLHAT study?
Topics: Adrenergic alpha-Antagonists; Anticholesteremic Agents; Antihypertensive Agents; Clinical Trials as | 2006 |
Are all alpha-blockers created the same?
Topics: Adrenergic alpha-Antagonists; Adult; Clinical Trials as Topic; Dizziness; Doxazosin; Humans; Male; M | 2006 |
Benign prostatic hyperplasia (BPH).
Topics: Adrenergic alpha-Antagonists; Doxazosin; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; | 2006 |
Linguistic adaptation and validation of the Spanish version of the Benign Prostatic Hyperplasia-Patient Impact Measure (BPH-PIM).
Topics: Adult; Aged; Aged, 80 and over; Doxazosin; Humans; Linguistics; Male; Middle Aged; Prostatic Hyperpl | 2006 |
Editorial comment on: Immunohistochemical distribution of cyclic GMP-dependent protein kinase-1 in human prostate tissue.
Topics: Actins; Adrenergic alpha-Antagonists; Aged; Animals; Blotting, Western; Cyclic GMP; Cyclic GMP-Depen | 2007 |
Intraoperative floppy-iris syndrome with doxazosin.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Cataract Extraction; Doxazosi | 2007 |
Incidence of intraoperative floppy iris syndrome in patients on either systemic or topical alpha1-adrenoceptor antagonist.
Topics: Administration, Topical; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adul | 2007 |
The influence of alpha1-antagonist on the expression pattern of TNF receptor family in primary culture of prostate epithelial cells from BPH patients.
Topics: Adrenergic alpha-Antagonists; Aged; Apoptosis; CD40 Antigens; Dose-Response Relationship, Drug; Doxa | 2008 |
Advances in the medical management of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Doxazosin; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyp | 2007 |
Physiologic reactivity to a laboratory stress task among men with benign prostatic hyperplasia.
Topics: Aged; Blood Pressure; Doxazosin; Finasteride; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System | 2007 |
Efficacy and safety of the alpha-1 blocker doxazosin in the treatment of benign prostatic hyperplasia. Analysis of 5 studies. Doxazosin Study Groups.
Topics: Aged; Aged, 80 and over; Blood Pressure; Double-Blind Method; Doxazosin; Heart Rate; Humans; Male; M | 1993 |
[Doxazosin in the treatment of benign prostatic hypertrophy].
Topics: Adult; Aged; Aged, 80 and over; Doxazosin; Humans; Male; Middle Aged; Prostatic Hyperplasia; Urodyna | 1993 |
Profile of doxazosin in the hypertensive man with benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Clinical Trials as Topic; Doxazosin; Humans; Hypertension; Male; | 1994 |
Reproducibility of uroflow measurement: experience during a double-blind, placebo-controlled study of doxazosin in benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Controlled Clinical Trials as Topic; Double-B | 1996 |
Effects of selective and nonselective alpha-1-adrenoceptor antagonists on intraurethral and arterial pressures in intact conscious dogs.
Topics: Adrenergic alpha-Antagonists; Animals; Blood Pressure; Dogs; Doxazosin; Male; Prazosin; Prostatic Hy | 1996 |
[Actual evaluation of pharmacologic treatment for benign changes in the prostate gland (prostate:lrs)].
Topics: Adrenergic alpha-Antagonists; Cholestenone 5 alpha-Reductase; Doxazosin; Humans; Male; Oxidoreductas | 1997 |
Transforming growth factor beta 1 transduced mouse prostate reconstitutions: II. Induction of apoptosis by doxazosin.
Topics: Adrenergic alpha-Antagonists; Animals; Apoptosis; Cells, Cultured; Disease Models, Animal; Doxazosin | 1997 |
Ambulatory urodynamic evaluation of men with lower urinary tract symptoms treated with doxazosin.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Doxazosin; Humans; Male; Middle Aged; Monitor | 1997 |
The treatment of benign prostatic hyperplasia with alpha blockers in men over the age of 80 years.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Blood Pressure; Doxazosin; Humans; Male; Praz | 1997 |
[The doxazosin treatment of the changes in the bladder filling phase in benign prostatic hyperplasia].
Topics: Adrenergic alpha-Antagonists; Aged; Doxazosin; Drug Evaluation; Humans; Male; Middle Aged; Prospecti | 1997 |
The effect of age in the usage of alpha receptor blocker treatment in prostate patients.
Topics: Adrenergic alpha-Antagonists; Age Factors; Aged; Data Interpretation, Statistical; Doxazosin; Humans | 1997 |
[Doxazosin treatment of disorders of the voiding phase in benign prostatic hyperplasia].
Topics: Adrenergic alpha-Antagonists; Aged; Doxazosin; Humans; Male; Middle Aged; Muscle Contraction; Prospe | 1997 |
Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Apoptosis; Cell Division; Doxazosin; Humans; Male; Middle Aged; | 1998 |
Benign prostatic hyperplasia and hypertension.
Topics: Antihypertensive Agents; Doxazosin; Erectile Dysfunction; Humans; Hypertension; Male; Prostatic Hype | 1998 |
Influence of the alpha1-adrenergic antagonist, doxazosin, on noradrenaline-induced modulation of cytoskeletal proteins in cultured hyperplastic prostatic stromal cells.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Cell Differentiation; Cells, | 1999 |
Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Apoptosis; Cell Division; Doxazosin; Humans; | 1999 |
Modulation of the differentiation status of cultured prostatic smooth muscle cells by an alpha1-adrenergic receptor antagonist.
Topics: Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Agon | 1999 |
A multicenter, community-based study of doxazosin in the treatment of concomitant hypertension and symptomatic benign prostatic hyperplasia: the Hypertension and BPH Intervention Trial (HABIT).
Topics: Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents; Blood Pressure; Doxazosin; Humans; Hype | 1999 |
Doxazosin-to-terazosin switch for benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Doxazosin; Drug Prescriptions; Humans; | 1999 |
Detrusor contraction duration may predict response to alpha-blocker therapy for lower urinary tract symptoms.
Topics: Adrenergic alpha-Antagonists; Doxazosin; Humans; Male; Middle Aged; Muscle Contraction; Predictive V | 2000 |
Modulating effect of estrogen and testosterone on prostatic stromal cell phenotype differentiation induced by noradrenaline and doxazosin.
Topics: Actins; Adrenergic alpha-Antagonists; Cell Differentiation; Cells, Cultured; Doxazosin; Estradiol; F | 2000 |
Effects of alpha(1)-adrenoceptor (alpha(1)-AR) antagonists on cell proliferation and apoptosis in the prostate: therapeutic implications in prostatic disease.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Apoptosis; Biopsy; Cell Divis | 2000 |
Transurethral resection of the prostate: failure patterns and surgical outcomes in patients with symptoms refractory to alpha-antagonists.
Topics: Adrenergic alpha-Antagonists; Aged; Comorbidity; Doxazosin; Humans; Louisiana; Male; Postoperative C | 2000 |
Initiation of nonselective alpha1-antagonist therapy and occurrence of hypotension-related adverse events among men with benign prostatic hyperplasia: a retrospective cohort study.
Topics: Accidental Falls; Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents; Cohort Studies; Comor | 2001 |
On call. I'm a 76-year-old man with an enlarged prostate. I've been taking Cardura and it's helped a lot, but my doctor stopped it because he said a study found the drug could cause heart failure. Now I'm getting up three or four times a night again. Is C
Topics: Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents; Doxazosin; Heart Failure; Humans; Hyper | 2001 |
Efficacy and tolerability of drugs for treatment of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Doxazosin; Enzyme Inhibitors; Finasteride; Humans; Male; Middle | 2001 |
Observational multicentric trial performed with doxazosin: evaluation of sexual effects on patients with diagnosed benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Case-Control Studies; Doxazosin; Follow-Up Studies; Humans; Male; Peni | 2002 |
Stroke associated with alpha blocker therapy for benign prostatic hypertrophy.
Topics: Adrenergic alpha-Antagonists; Doxazosin; Humans; Male; Middle Aged; Prostatic Hyperplasia; Stroke | 2002 |